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ABSTRACT 
 
Tuula Siljander, Molecular and epidemiological aspects of Streptococcus pyogenes 
disease in Finland: Severe infections and bacterial, non-necrotizing cellulitis. 
National Institute for Health and Welfare, Research 23|2009. 160 pages. Helsinki, 
Finland 2009. ISBN 978-952-245-174-3 (print); ISBN 978-952-245-175-0 (pdf) 
 
Background and aims. Streptococcus pyogenes (group A streptococcus, GAS) 
causes a variety of infections ranging from mild pharyngitis to severe, invasive 
infections such as bacteraemia. The predominant GAS strains in invasive disease 
vary over time and geographic region. In 2006, the Finnish nationwide surveillance 
showed an increase in invasive GAS disease, and clinicians were alarmed by the 
severe disease manifestations and poor outcome. These events prompted 
investigation of recent trends in incidence, outcome, and bacterial types. Bacterial, 
non-necrotizing cellulitis and erysipelas are localised and potentially recurrent 
infections of the skin. The aim of the study was to identify the β-haemolytic 
streptococci causing cellulitis and erysipelas infections in Finland.  
 
Methods. This study was based on national, population-based surveillance for 
invasive group A streptococcal (iGAS) disease. A case was defined as S. pyogenes 
isolated from blood or cerebrospinal fluid. Cases and the corresponding isolates 
were included during 1995-2007. Case-patients’ 7-day outcome was obtained for 
2004-2007. Isolates during 1995-2006 were T serotyped and during 2004-2007 emm 
typed. Additionally, all serotype T28 isolates since 1995 were emm typed. Isolates 
of an uncommon type emm84 were characterised by pulsed-field gel electrophoresis 
(PFGE) and superantigen profiling. Susceptibility to erythromycin, clindamycin and 
tetracycline was determined for all isolates during 2004-2007 and to levofloxacin 
during 2005-2007.  
 
A case-control study of patients hospitalised for acute non-necrotizing cellulitis was 
conducted during April 2004-March 2005. Bacterial swab samples were obtained 
from skin lesions; blood culture samples were taken for detection of bacteraemia. 
Throat cultures of patients, family members and control subjects were assessed for 
pharyngeal carrier status. β-haemolytic streptococci and Staphylococcus aureus 
were isolated and identified; group A and G streptococci were analysed by T and 
emm typing and PFGE. 
 
Results. During 1995-2007, the annual incidence of iGAS disease fluctuated (range 
by year, 1.1-3.9 cases per 100,000 population) but had an increasing trend, with 
peaks in 2002 (2.9) and in 2006-2007 (3.1-3.9). During 1998-2007, 1318 cases of 
iGAS were identified (55% in males), with an average annual incidence of 2.5 cases 
  
per 100,000. Males had a higher incidence than females, especially among persons 
aged 45-64 years, while females had a higher incidence than males among persons 
aged 25-34 years. Occasional peaks of cases occurred during midwinter and 
midsummer. During 1995-2007, a total of 1457 iGAS isolates were analysed. The 
five most prevalent T types during 1995-2006 were T28 (29%), T1 (13%), TB3264 
(12%), T12 (7%) and T8 (6%). The most common emm types during 2004-2007 
were 28 (21%), 1 (16%), 84 (10%), 75 (7%), and 89 (6%). The prevalence of types 
T/emm1 and T/emm28 fluctuated during the study, with T/emm1 being the most 
predominant type in 1997-1998 and 2007 and T/emm28 in 1995-1996 and 2000-
2006. Among T28 isolates, six different emm types were found during 1995-2006, 
with emm28 predominating. Among emm84 isolates, six PFGE strain types, with 
one dominating clone were found. Overall, 1.5% of the isolates were resistant to 
erythromycin, 0.5% to clindamycin and 16% to tetracycline. Females, especially of 
child-bearing age (15-44 years), had more infections by emm28 than males. The 
overall 7-day case fatality during 2004-2007 was 8%, peaking in 2005 (12%). Cases 
with emm1 infections were associated with higher than average case fatality (14%), 
whereas that of emm84 was 7%, and of emm28 only 2%.  
 
A total of 90 patients with acute non-necrotizing cellulitis, 90 control subjects and 
38 family members were recruited to a case-control study. β-haemolytic streptococci 
were isolated from 26 (29%) of 90 patients, either from skin lesions (24 patients) or 
blood (2 patients). Group G streptococcus (GGS, Streptococcus dysgalactiae subsp. 
equisimilis) was isolated most commoly (22%), followed by GAS (7%). GGS was 
also carried in the pharynx of 7% of patients and 13% of household members but 
was missing in control subjects. Several emm and PFGE types were found among 
the isolates. Six patients (7%) had recurrent infections during the study. In two 
patients, the same strain of GGS with identical emm and PFGE types was isolated 
from two consecutive episodes.  
 
Conclusions. The incidence of iGAS disease had an increasing trend during the past 
ten years in Finland. Age- and sex-specific differences in the incidence rate and 
seasonal patterns were observed, and presumably differences in the predisposing 
factors and underlying conditions contribute to these distinctions. Changes in the 
emm type prevalence were associated with the increase in incidence and case 
fatality. The case fatality rate for S. pyogenes infections remained at a reasonably 
low level (8% overall) compared to that of other developed countries (mostly 
exceeding 10%). emm typing is sufficient for general epidemiological surveillance 
of iGAS disease, but for cluster or outbreak investigations, higher discriminatory 
power can be achieved when it is complemented by other techniques, such as  
PFGE.  
  
In the case-control study, unexpectedly GGS, instead of GAS, predominated in acute 
non-necrotizing cellulitis. A predominance of GGS was also seen in the throat of 
case-patients and their family members, but not in control subjects. No clear 
predominance of a specific emm type was seen. The recurrent nature of cellulitis 
became evident.  
 
This study adds to our understanding of the molecular epidemiology of S. pyogenes 
infections in Finland and provides a basis for comparison to other countries and 
future trends. Global emm type and outcome surveillance remain important in order 
to detect changes in the type distribution potentially leading to increasing incidence 
and case fatality.  
 
Keywords: bacteraemia; cellulitis; emm typing; epidemiology; erysipelas; outcome; 
Streptococcus dysgalactiae subsp. equisimilis; Streptococcus pyogenes. 
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Tausta ja tavoitteet. Streptococcus pyogenes (A-ryhmän streptokokki, GAS) 
aiheuttaa vakavuusasteeltaan vaihtelevia infektioita, lievistä hengitystieinfektioista 
vakaviin, invasiivisiin infektioihin, kuten bakteremioihin. Invasiivisia infektioita 
aiheuttavien A-ryhmän streptokokkikantojen vallitsevat tyypit vaihtelevat 
maantieteellisesti ja eri ajankohtina. Kansallinen seuranta osoitti invasiivisten 
streptokokki-tautitapausten lisääntyneen Suomessa vuonna 2006, ja hoitavat lääkärit 
huolestuivat kuolemaan johtavista vakavista taudinkuvista. Tämän johdosta 
käynnistettiin tutkimus taudin ilmaantuvuuden, kuolleisuuden ja bakteerityyppien 
viimeaikaisista suuntauksista. Bakteerin aiheuttama selluliitti ja erysipelas 
(ruusutulehdus) ovat paikallisia ja potentiaalisesti uusiutuvia ihon ja 
ihonalaiskudoksen infektioita. Tutkimuksen tavoitteena oli tunnistaa Suomessa 
selluliitti- ja erysipelasinfektioita aiheuttavia β-hemolyyttisiä streptokokkeja.   
 
Menetelmät. Tutkimus pohjautui kansalliseen ja väestöpohjaiseen invasiivisten A-
ryhmän streptokokkitautien seurantaan. Tapausmääritelmänä oli veren tai likvorin 
positiivinen S. pyogenes -viljelylöydös. Tapaukset ja niitä vastaavat bakteerikannat 
tutkittiin vuosilta 1995–2007. Tapauksiin liittyvä 7 päivän kuolleisuustieto oli 
saatavilla vuosille 2004–2007. Kannat vuosilta 1995–2006 T-serotyypitettiin ja 
vuosilta 2004–2007 emm-tyypitettiin. Lisäksi kaikki serotyyppiä T28 olevat kannat 
vuodesta 1995 asti emm-tyypitettiin. Harvinaista genotyyppiä emm84 olevat kannat 
karakterisoitiin käyttäen pulssikenttä-geelielektroforeesia (PFGE) ja 
superantigeenien määritystä. Kaikkien kantojen herkkyys erytromysiinille, 
klindamysiinille ja tetrasykliinille määritettiin vuosilta 2004–2007 ja 
levofloksasiinille vuosilta 2005–2007.  
 
Tapaus-verrokkitutkimus, jossa tutkittiin akuutin selluliitin takia sairaalahoitoon 
joutuneita potilaita, toteutettiin aikavälillä huhtikuusta 2004 maaliskuuhun 2005. 
Ihorikkoalueelta otettiin bakteeriviljely tikkunäytteenä; veriviljelynäytteet otettiin 
bakteremian havaitsemiseksi. Potilaiden, perheenjäsenten ja verrokkien 
nielukantajuutta arvioitiin nieluviljelyiden perusteella. Näytteistä eristettiin ja 
tunnistettiin β-hemolyyttisiä streptokokkeja sekä Staphylococcus aureus -kantoja ja 
A- ja G-ryhmän streptokokit analysoitiin T- ja emm-tyypityksellä ja PFGE:llä.  
  
Tulokset. Tutkimusjakson 1995–2007 aikana GAS-infektioiden ilmaantuvuus 
vaihteli (vuosittainen vaihteluväli 1,1–3,9 tapausta/100 000 henkilöä), mutta  
suuntaus oli nouseva ja huippuja esiintyi vuosina 2002 (2,9) ja 2006–2007 (3,1–3,9). 
Vuosien 1998–2007 aikana todettiin 1 318 invasiivista GAS-tapausta (joista 55 % 
miehiä) ja taudin keskimääräinen vuosittainen ilmaantuvuus oli 2,5 tapausta/100 000 
henkilöä. Miehillä, etenkin 45–64-vuotiailla, oli korkeampi taudin ilmaantuvuus 
kuin naisilla, joilla taas 25–34-vuotiaiden ikäryhmässä oli korkeampi ilmaantuvuus 
kuin miehillä. Tapausmäärissä havaittiin satunnaisia huippuja keskitalvella ja 
keskikesällä. Kaikkiaan 1 457 invasiivista GAS-kantaa analysoitiin vuosina 1995–
2007. Viisi yleisintä T-tyyppiä vuosina 1995–2006 olivat T28 (29 %), T1 (13 %), 
TB3264 (12 %), T12 (7 %) ja T8 (6 %). Yleisimmät emm-tyypit vuosina 2004–2007 
olivat 28 (21 %), 1 (16 %), 84 (10 %), 75 (7 %) ja 89 (6 %). Tyyppien T/emm1 ja 
T/emm28 yleisyys vaihteli tutkimuksen aikana, T/emm1 oli yleisin tyyppi vuosina 
1997–1998 ja 2007 ja T/emm28 vuosina 1995–1996 ja 2000–2006. T28-kantojen 
joukosta löytyi kuutta eri emm-tyyppiä vuosina 1995–2006, joista emm28 oli 
vallitseva. emm84-kantojen joukosta löytyi kuutta eri PFGE-kantatyyppiä, joista 
yksi vallitsi. Kaikista kannoista 1,5 % oli resistenttejä erytromysiinille, 0,5 % 
klindamysiinille ja 16 % tetrasykliinille. Naisilla, etenkin lapsensaanti-ikäisillä (15–
44-vuotiailla), oli enemmän emm28-tyypin infektioita kuin miehillä. 
Keskimääräinen tapauskuolleisuus 7 päivän kohdalla oli 8 % vuosina 2004–2007, ja 
se nousi huippuunsa vuonna 2005 (12 %). emm1-tyypin infektioihin liittyi 
keskimääräistä korkeampi tapauskuolleisuus (14 %), kun emm84-tyypin infektioissa 
se oli 7 % ja emm28-infektioissa vain 2 %.  
 
Kaikkiaan 90 selluliittipotilasta, 90 verrokkihenkilöä ja 38 perheenjäsentä 
rekrytoitiin tapaus-verrokkitutkimukseen. β-hemolyyttisiä streptokokkeja eristettiin 
26 potilaalta 90:stä (29 %), joko ihorikosta (24 potilasta) tai verestä (2 potilasta). 
Potilasnäytteistä löytyi yleisimmin (22 %) G-ryhmän streptokokki (GGS, 
Streptococcus dysgalactiae subsp. equisimilis) ja seuraavaksi yleisimmin (7 %) A-
ryhmän streptokokki. Potilaista 7 % ja perheenjäsenistä 13 % kantoi nielussaan G-
ryhmän streptokokkia, kun taas verrokeilta sitä ei löytynyt. Kannat edustivat useita 
emm- ja PFGE-tyyppejä. Tutkimuksen aikana kuudella potilaalla (7 %) oli toistuva 
infektio. Kahdella heistä voitiin eristää kahdesta peräkkäisestä infektiosta sama 
identtisen emm- ja PFGE-tyypin omaava GGS-kanta.  
 
Yhteenveto. Invasiivisten A-ryhmän streptokokki-infektioiden ilmaantuvuudessa oli 
nouseva suuntaus viimeisten kymmenen vuoden aikana Suomessa. 
Ilmaantuvuudessa ja vuodenaikaisvaihtelussa havaittiin ikä- ja sukupuolispesifisiä 
eroja, joihin vaikuttivat todennäköisesti erot potilaiden altistavissa tekijöissä ja 
perussairauksissa. Muutokset emm-tyyppijakaumassa liittyivät ilmaantuvuuden ja 
tapauskuolleisuuden nousuun.  S. pyogenes -infektioihin liittyvä tapauskuolleisuus 
  
pysyi kohtalaisen matalalla tasolla (keskimäärin 8 %) verrattuna muihin 
kehittyneisiin maihin (yleensä yli 10 %). emm-tyypitys on riittävä taudin yleiseen 
epidemiologiseen seurantaan, mutta ryppäiden ja epidemioiden selvittelyyn voidaan 
saada parempi erottelukyky kun menetelmää täydennetään muilla menetelmillä 
kuten PFGE:llä. 
 
Tapaus-verrokki-tutkimuksessa selluliitti-infektioista löytyi yllättäen enemmän G- 
kuin A-ryhmän streptokokkibakteeria. G-ryhmän streptokokki vallitsi myös nielussa 
potilailla ja perheenjäsenillä mutta ei verrokkihenkilöillä. Mikään tietty emm-tyyppi 
ei ollut vallitseva. Tutkimus vahvisti käsitystä selluliitti-infektioiden toistuvasta 
luonteesta.  
 
Tutkimus lisää tietoutta S. pyogenes -infektioiden molekyyliepidemiologiasta 
Suomessa ja luo pohjan vertailulle muiden maiden tilanteeseen ja tuleviin 
suuntauksiin. Maailmanlaajuinen emm-tyyppien seuranta ja kuolleisuustutkimukset 
ovat tärkeitä, jotta voidaan havaita sellaisia muutoksia tyyppijakaumassa, jotka 
voivat johtaa ilmaantuvuuden ja kuolleisuuden kasvuun.  
 
Asiasanat: bakteremia; emm-tyypitys; epidemiologia, erysipelas; kuolleisuus, 
selluliitti; Streptococcus dysgalactiae subsp. equisimilis; Streptococcus pyogenes. 
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1  INTRODUCTION 
Streptococcus pyogenes (group A streptococcus, GAS) is an organism that is able to 
cause a wide array of infections in humans. The disease manifestations can range in 
severity from mild upper respiratory tract infections and skin and soft tissue 
infections to the severe invasive infections, such as bacteraemia, pneumonia, 
necrotizing fasciitis, and streptococcal toxic shock syndrome. Infections caused by 
Streptococcus pyogenes are among the most ubiquitous which make this a very 
important human pathogen.  
 
S. pyogenes has complex virulence mechanisms, which contribute to its efficiency as 
a pathogen. The major virulence factor of GAS is the M protein, which is expressed 
in abundance on the bacterial surface and encoded by the emm gene. The outer part 
of the M protein is extremely variable, and this hypervariability has been used as the 
basis for a serological typing method (M typing) since the 1960s [187]. Currently, 
the most widely used typing method of GAS is based on sequencing the 
hypervariable part of the emm gene. Well over a hundred distinct emm sequence 
types have been identified among GAS strains [17, 100, 101]. 
 
The majority of GAS infections are mild pharyngeal infections and skin infections. 
Tens of thousands of streptococcal pharyngitis cases occur annually in Finland. In 
contrast, severe streptococcal diseases occur only in 1-10 persons per 100,000 
population in developed countries annually (currently around 200 cases per year in 
Finland). Attempts to control and eradicate these infections are important for several 
reasons. Firstly, mild infections can lead to a more severe disease, and patients with 
mild infections can transmit the bacteria to others. Although the severe GAS 
diseases are relatively rare, they constitute a major global burden, resulting in 
hundreds of thousands of cases each year, most of which occur in less-developed 
countries [43]. Secondly, despite antimicrobials and other medical treatment, severe 
infections are associated with a high mortality rate even exceeding 40% [244]. 
Group A streptococcus has been estimated to be among the ten most common causes 
of death due to individual pathogens globally [43]. A quarter to a fifth of cases have 
no predisposing factors to infection, and the infections can affect people of all ages 
[185]. These characteristics also contribute to fear and anxiety in the general public 
and media, referring to this pathogen as “the killer bug” or “the flesh-eating 
bacterium”.  
 
In the late 1980s, a change in the epidemiology of severe group A streptococcal 
infections, with an increase in the incidence and severity of disease, was 
documented by many countries [140, 157, 270, 295, 300]. The role and pathogenic 
potential of especially type M1, but also of M3, in the epidemics were of specific 
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interest [53, 204, 300]. The incidence of invasive GAS (iGAS) disease typically 
varies by time and geographic region, and this presumably reflects a population’s 
susceptibility to particular strains but also the natural variation in the predominant 
types [242]. Variation in the type distribution may also lead to fluctuation in the 
severity of infections and mortality rates.  
 
Bacterial erysipelas and cellulitis refer to acute, diffuse, spreading infections of the 
skin and subcutaneous tissue. Group A streptococcus has been considered the main 
causative agent of erysipelas and cellulitis, although streptococci of other groups can 
also cause these infections [37, 49, 94]. Although erysipelas and cellulitis are 
usually not life-threatening infections, they have an unfortunate tendency to recur 
and therefore cause remarkable morbidity, especially in elderly patients [31, 94, 116, 
162]. Pharyngeal streptococcal colonisation might be a risk factor for a symptomatic 
infection. Many other general and local risk factors and individual differences in 
immune response can influence the susceptibility to infections and to recurrences. 
Distinguishing between erysipelas and cellulitis may be impossible based only on 
the clinical picture of the infection [31].  
 
Molecular epidemiology focuses on characterisation of molecular properties of the 
causative pathogen in infectious diseases. Surveillance is of importance in order to 
rapidly detect changes in type distribution or resistance to antimicrobials. Several 
approaches for developing an effective and safe vaccine against S. pyogenes 
infections have been made, but vaccine development for this organism has proven 
very challenging. Identification of strain types also serves as a basis for studies of 
disease pathogenesis and vaccine development [244]. 
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2  REVIEW OF THE LITERATURE 
2.1 Human pathogenic β-haemolytic streptococci 
Streptococci are gram-positive, facultatively anaerobic cocci-shaped bacteria, which  
occur in pairs or chains and include many different species (including Streptococcus 
pyogenes) infecting humans and animals. The name Streptococcus literally means a 
chained round-shaped bacteria and pyogenes refers to pus formation by this 
bacterium. The classification of streptococci is based on their haemolysis - α, β, and 
γ - on blood agar plates, which result in partial, complete, or no lysis of red blood 
cells, respectively. β-haemolysis shows on a blood agar plate as a clear zone around 
the bacterial colonies. Dr. Rebecca Lancefield was the first to develop a method for 
classification of β-haemolytic streptococci by serologically detecting their group-
specific polysaccharide antigens [186]. The human pathogenic β-haemolytic 
streptococci generally include the Lancefield serogroups A, B, C and G [99]. The 
distinction of serogroups does not fully follow the species determination of 
streptococci, as is shown in Table 1, which outlines the taxonomy within these 
Lancefield groups. Rarely, strains of S. dysgalactiae subsp. equisimilis possess the 
group A antigen. Besides the species covered by the table, many other streptococcal 
species causing infections in animals exist.  
Table 1. The most important human pathogenic β-haemolytic streptococci (adapted 
from [99]) 
Species  Lancefield group Origin 
Streptococcus pyogenes A human 
S. agalactiaea B human, bovine 
S. dysgalactiae subsp. equisimilis A, C, G, L human, animals 
S. equi subsp. zooepidemicus C animals, human 
S. canis G dog, human 
S. anginosus (group)b A, C, G, F, none human 
S. constellatus subsp. pharynges C human 
a S. is abbreviation for Streptococcus. 
b The S. anginosus group includes β-haemolytic strains of S. anginosus, S. constellatus and S. 
intermedius.  
 
The β-haemolytic streptococci of groups A, C and G colonise humans and cause 
clinically similar mild and more severe infections. In particular, bacteraemic strains 
of group G and C streptococcus (S. dysgalactiae subsp. equisimilis) seem to share 
characteristics of pathogenic potential with group A strains [99, 114]. In contrast, 
group B streptococcus (GBS) has traditionally caused infections predominantly in 
neonates and pregnant women but these infections have lately increased also among 
nonpregnant adults with underlying diseases and the elderly [105, 269].  
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2.2 Streptococcus pyogenes; group A streptococci 
2.2.1 Carriage and transmission 
Streptococcus pyogenes is strictly a human pathogen [294]. It can be carried 
asymptomatically on the skin (superficial layers of the epidermis) and mucous 
membranes, such as the oropharyngeal mucosal epithelium, the nasal epithelium 
(although less commonly), the genital tract, and the perianal area [13, 294]. A 
pharyngeal GAS carrier can be defined as an asymptomatic individual with a 
positive throat culture and no active immune or inflammatory response, or an 
asymptomatic child who tests positive for GAS after completing accurate 
antimicrobial treatment of GAS pharyngitis [205, 311]. The latter definition refers to 
chronic carriage. 
 
School-aged children (5-15 years) are considered as the major reservoir of GAS, 
with a prevalence of pharyngeal carriage of 15-25% or more depending on the study 
setting [55, 128, 205, 311]. Adults, in contrast, have low pharyngeal carrier rates 
(<5%) [294]. The carrier state may vary by age, season, and geographical location 
[128, 205]. Carriage can be transient or persistent, and the carried strain can be 
replaced by a new type of GAS [205, 311]. Internalisation of GAS into epithelial 
cells, protecting the pathogen from antimicrobial treatment, has been suggested as a 
mechanism for persistent throat carriage [247, 271].  
 
The bacteria can be transmitted from carriers and especially those with pharyngeal 
disease to other persons and the surroundings by direct contact with respiratory 
secretions or by aerosolised droplets [55, 137, 205, 294]. Crowded living conditions, 
such as day-care centers or military settings, favour the transmission of the bacteria 
[137, 277].  
 
2.2.2 Diseases caused by S. pyogenes 
Streptococcus pyogenes causes a wide array of disease manifestations ranging in 
severity. Diseases presumably caused by S. pyogenes (and other streptococcal 
species) were already described in the 18th and 19th century, long before there was 
any knowledge of streptococci as the causative agent, or that many of the different 
disease manifestations were actually caused by the same organism. In 1874, 
Theodor Billroth demonstrated the existence of streptococci in patients with 
erysipelas and wound infections and was the first to use the term streptococcus [3, 
77]. 
 
The most common superficial infections caused by GAS are upper respiratory tract 
infections, including acute tonsillitis (“strep-throat”) or pharyngitis [32, 77]. GAS 
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can also cause otitis media and sinusitis. Scarlet fever is caused by strains of S. 
pyogenes which express one or more of certain pyrogenic exotoxins (A, B or C), and 
this disease is thus accompanied by toxin-mediated symptoms, such as a 
characteristic rash, “strawberry” tongue, and desquamation of the skin [64]. Scarlet 
fever used to be a life-threatening infection before the era of antimicrobials, 
commonly causing epidemics with a high mortality, but it is now a milder disease, 
most frequently presented by a pharyngitis accompanied by the distinctive rash [173, 
293]. 
  
S. pyogenes causes a wide variety of skin and soft-tissue infections. Impetigo (or 
pyoderma) is a superficial, localised and purulent infection of the dermis and 
epidermis. It is more common in humid and warm climates, usually occurring in 
children, and usually on exposed areas such as the face, hands or feet [31, 197]. 
Erysipelas and cellulitis, which are more deeply situated non-necrotizing infections 
of the skin and underlying tissue, are discussed in more detail in section 2.2.3. 
Necrotizing fasciitis (NF) is a severe infection of the deeper subcutaneous tissue and 
fascia [304]. It presents with severe local pain and rapid tissue destruction and leads 
to systemic symptoms, which may include shock and multiorgan failure, and 
subsequently, death.  
 
In addition to the above-mentioned infections, S. pyogenes can also cause other 
localised infections, such as meningitis, peritonitis, pneumonia, septic arthritis, and 
puerperal sepsis (see also section 2.3.4.). Puerperal sepsis, an infection 
predominantly caused by GAS and also known as “childbed fever”, was formerly a 
much dreaded disease and a common cause of death for young women in Europe in 
the 18th and 19th centuries [7, 77]. Epidemics with a high mortality (50% or more) 
were commonly seen in maternity wards due to transfer of bacteria to women by the 
hands of attending physicians, who had previously been performing autopsies or 
examining other patients [3, 7, 77]. One contributory factor to the epidemics was the 
fundamental change in the society towards giving birth in large maternity hospitals 
instead of at home [7]. These days, with the use of aseptic techniques and treatments 
available, the mortality due to puerperal sepsis is estimated at 3.5% or less, although 
outbreaks still occur [51].   
 
A focal infection may or may not be associated with bacteraemia, which by 
definition means the presence of cultivatable bacteria in the bloodstream, a state that 
may also be transient and inconsequential, in contrast to sepsis, which refers to the 
body’s systemic response to infection [227]. On occasion, the focus of the infection 
cannot be identified, with the only disease manifestation being bacteraemia due to S. 
pyogenes. Some of the infections by S. pyogenes, especially NF, are associated with 
a most severe complication, streptococcal toxic shock syndrome (STSS), which 
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involves hypotension, shock, and multiorgan failure and consequently leads to high 
mortality [1]. STSS and scarlet fever can be regarded as toxin-mediated diseases 
caused by S. pyogenes [88]. 
 
On occasion, GAS infection can be followed by an inappropriate immunologically-
mediated response and tissue-specific damage. These non-suppurative complications 
of S. pyogenes include acute post-streptococcal glomerulonephritis (APSGN) and 
acute rheumatic fever (ARF). ARF is a sequela of an untreated infection of the upper 
respiratory tract, and it can lead to the development of rheumatic heart disease, 
whereas APSGN can also be associated with a skin infection [88, 203]. The clinical 
manifestations of APSGN or ARF occur approximately 3 weeks after the underlying 
infection, and they are caused by the so-called nephritogenic or rheumatogenic 
strains, respectively [88, 145, 203]. These post-infectious streptococcal diseases are 
more common in developing countries, where rheumatic heart disease is the most 
common cardiac disease in children and young adults [43]. These infections used to 
be more common in the developed countries, such as the USA, but their prevalence 
has markedly decreased during recent decades [278].  
 
Table 2 presents the classification of S. pyogenes diseases and streptococcal toxic 
shock syndrome, as originally defined by the USA Working Group and used by 
many countries for surveillance purposes [1]. The classification includes a division 
of diseases caused by S. pyogenes into invasive and noninvasive, where invasive 
disease refers to isolation of S. pyogenes from a normally sterile site. The term 
“severe GAS diseases” may also be used and it can be regarded to include invasive 
disease, acute rheumatic fever, rheumatic heart disease, and acute post-streptococcal 
glomerulonephritis [43].  
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Table 2. Classification of streptococcal infections (adapted from [1]) 
I.   Streptococcal toxic shock syndrome (STSS)a 
1. Isolation of S. pyogenes from a normally sterile site or from a nonsterile site 
2. Clinical signs of severity 
A. Hypotension, and: 
B. ≥2 of the following signs: renal impairment, coagulopathy, liver 
involvement, adult respiratory distress syndrome, erythematous rash, 
soft-tissue necrosis including NF 
II.  Other invasive infections: isolation of S. pyogenes from a normally sterile site in 
patients not meeting criteria for STSS 
A. Bacteraemia with no identified focus 
B. Focal infections with or without bacteraemia 
III. Scarlet fever: a scarlatina rash with evidence of S. pyogenes infection such as 
pharyngotonsillitis 
IV. Noninvasive infections: isolation of S. pyogenes from a nonsterile site 
A. Mucous membrane 
B. Cutaneous 
V.   Nonsuppurative sequelae 
A.   Acute rheumatic fever 
B.   Acute glomerulonephritis 
a A definite or probable case of STSS depending on fulfilling the criteria. 
 
2.2.3 Streptococcal non-necrotizing cellulitis  
Bacterial non-necrotizing cellulitis refers to an acute, diffuse, spreading infection of 
the skin and subcutaneous tissue, excluding cutaneous abscesses, necrotizing 
fasciitis, septic arthritis, and osteomyelitis [296]. Cellulitis usually refers to a more 
deeply situated skin infection, with a diffuse swelling and reddening of the skin 
without a clear boundary, whereas erysipelas can be considered as a superficial form 
of cellulitis, usually being manifested by a well-demarcated erythema of the skin. 
The distinction between cellulitis and erysipelas is not clear-cut, and these 
conditions share typical clinical features – for example, local signs of inflammation 
and sudden onset, usually with a high fever [31]. If the clinical diagnosis is not 
always straightforward, neither is the terminology. The terms erysipelas and 
cellulitis are used inconsistently, partly due to the customary use of the term 
erysipelas, especially in some parts of Europe, to describe both infections, whereas 
in the USA only the term cellulitis is used to cover both infections. In this book, the 
term cellulitis is used to encompass all non-necrotizing cellulitis and erysipelas 
infections caused predominantly by streptococci if not otherwise specified.  
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S: pyogenes has been considered to be the main causative agent of erysipelas and 
cellulitis, although streptococci of group G and C (most importantly, Streptococcus 
dysgalactiae subsp. equisimilis), group B, and rarely, staphylococci can also be 
involved in these infections, sometimes concomitantly with streptococci [35, 37, 48, 
94, 148]. The role of Staphylococcus aureus as a causative pathogen is believed to 
be larger in cellulitis as compared to classic erysipelas infections [304]. Colonisation 
of the skin by the pathogen is frequently observed during the infection [37, 161]. 
Patient blood cultures are positive for β-haemolytic streptococci in only <5% of 
cases [31, 37, 48, 94, 161]. The role of streptococcal toxins contributing to local 
inflammation is probably very important in the pathogenesis of this disease [37].  
 
The predominant infection site is the legs; the face or arms are more rarely affected 
[37, 48]. Known risk factors for infection include lymphoedema and, most notably, 
disruption of the cutaneous barrier, such as local trauma, leg ulcer, toe-web 
intertrigo, and chronic fungal infections, which provide a site of entry for the 
pathogen(s) [35, 37, 87, 133, 223, 265]. A portal of entry is mostly found but it is 
not always possible to affirm it as such [48, 87]. Other local risk factors are 
lymphatic congestion, venous or arterial insufficiency, and a previous history of a 
cellulitis infection [35, 162]. Among the general risk factors, being overweight, 
diabetes, smoking, and alcoholism are worth mentioning although they have been 
variably identified depending on the study [48, 87, 162, 264]. In some studies, a 
slight male predominance has been identified in patients with cellulitis [35, 191, 
223].  
 
In Finland, the recommended antimicrobial treatment for streptococcal cellulitis is 
penicillin administered either intravenously or intramuscularly, and after the 
recovery has started (usually after 3-5 days), followed by oral administration for a 
total of three weeks [85]. For patients who are penicillin-allergic, cephalosporins are 
recommended, or, alternatively, clindamycin in cases with severe penicillin allergy. 
Antimicrobials other than penicillin are needed for infections where Staphylococcus 
aureus is suspected or confirmed, either as the sole pathogen or concomitantly with 
a streptococcus [31, 37, 85]. An Italian study suggested that the course of 
polymicrobial cellulitis may be more severe than monomicrobial infection, with 
these cases more likely to have open skin lesions with a heavier bacterial load in the 
infection site and to require a longer stay in hospital [190].    
 
Twenty to 30% of cellulitis patients have a recurrence within a 3-year follow-up 
period [94, 162]. According to some studies, recurrences share mostly the same risk 
factors as the first episodes of infection, identified as lower extremity oedema, high 
body mass index, and smoking [191, 194]. Usually after a certain number of 
recurrences, long-term prophylaxis with daily oral penicillin or monthly benzathine 
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penicillin injections is initiated [37, 48]. It is also important to treat the portal of 
entry, most often the toe-web intertrigo or chronic mycosis, to prevent further 
recurrences [62, 87, 265]. Anal colonisation with streptococci may also constitute a 
reservoir for relapsing cellulitis infections [37, 95]. Although cellulitis infections are 
usually not life-threatening, they cause remarkable morbidity especially in the 
elderly patients and considerable costs arise from hospitalisation [31, 116].   
 
2.2.4 Virulence factors 
S. pyogenes has very complex virulence mechanisms, which is illustrated by the fact 
that more than 60 properties relating to this pathogen’s virulence have been 
described so far [213]. The qualities that constitute a virulence factor include those 
which confer antiphagocytic properties, adherence to epithelial cells, internalisation 
into cells, invasion, spread through tissues or systemic toxicity [34]. Nearly all 
surface components of GAS have been suggested to be virulence-associated, but the 
most important structures for virulence seem to be the capsule and M proteins, as 
discussed next [152].  
 
As the first line of defence, group A streptococci have a hyaluronic acid capsule, 
which is poorly immunogenic, protects the pathogen from phagocytosis, and is 
involved in adherence and invasion [65, 329]. Streptococcal strains vary greatly in 
their degree of capsular expression, and very mucoid strains with heavy 
encapsulation have been linked more often to invasive infections as well as ARF 
[34, 299]. The cell wall consists of peptidoglycan with lipoteichoid acid 
components, which may also play a role in the pathogenesis by binding to 
fibronecting and thus facilitating the adherence to pharyngeal epithelial cells [34]. It 
is not clear if the group carbohydrate, which is attached in the cell wall and confers 
the serologic group specificity, has a role in pathogenesis. 
 
M protein, encoded by the emm gene, is the most abundant surface protein of 
streptococci and the major virulence factor of GAS. Strains not expressing M 
protein are non-virulent [33]. M protein is a highly polymorphic protein of 41-80 
kDA in size, and its structure resembles that of the staphylococcal A protein. It has a 
dimeric α-helical coiled-coil structure, which forms fibres (of 50-60 nm in length) 
that protrude outwards from the cell wall (Figure 1) [109]. The N-terminal outer part 
of the protein has a hypervariable sequence, while the C-terminal part, associated to 
the cell wall and membrane, is conserved.  
 
The α-helical structure of the protein consists of a repeating seven-residue amino 
acid pattern, which tolerates a considerable amount of variation in the primary 
sequence. The amino acid variation, resulting in irregularity and instability of the 
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coiled-coil structure, has been found to be a requisite for virulence [214]. The 
protein also contains a series of tandem repeat regions (A-C) of different sizes, 
which vary by M type. The hypervariability in the aminoterminal part forms the 
basis for M and emm typing, which are described in more detail in section 2.2.6. In 
addition to GAS, group C and G streptococci infecting humans also harbour 
heterogeneous M proteins [33, 41, 58].   
 
Figure 1. A schematic representation of the streptococcal M protein. Adapted from 
[109, 110]. 
 
 
M proteins are part of a protein family of M-like proteins, which have homology to 
several human proteins, such as the heavy chain of cardiac myosin, type I keratins, 
and human α-tropomyosin [109]. Many GAS strains possess more than one M-like 
protein, encoded by emm-like genes in the Mga (multiple gene regulator) regulon 
(also discussed later in this section). There are four major subfamilies of emm genes, 
and the chromosomal arrangement of them reveals five major emm patterns A-E [28, 
27, 210]. These patterns can act as genotypic markers for tissue-site preferences 
among S. pyogenes strains. Studies suggest that horizontal transfer events of emm-
like gene sequences between strains of S. pyogenes have commonly occurred, 
contributing to the evolution of these genes [331, 330]. There is indeed evidence that 
the evolution of the transcription regulatory gene mga (multiple gene regulator) is 
linked to the tissue tropism (niche specialisation) of S. pyogenes, which may explain 
the associations of emm types to certain disease manifestations (see also section 
2.3.6) [28]. The M proteins are involved in the virulence of GAS infections by many 
different mechanisms, which are described next.  
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Group A streptococci are primarily located in the extracellular space during 
infections, although they can also exist intracellularly within phagocytic cells [317]. 
The main host defences against the pathogen are the complement, the antibodies, 
and the phagocytic cells, which are targeted at extracellular pathogens [152]. 
Complement is the primary host defence against pathogens in the human blood. It is 
a system consisting of several soluble serum proteins and regulatory proteins that 
form part of the innate (non-adaptive) immune response system. The activation of 
either the classical or the alternative pathway of complement leads to the 
opsonisation (coating) of the target with complement protein C3b. The M protein 
interferes with this defence mechanism by resisting opsonisation and the subsequent 
phagocytosis and killing by human leukocytes [34]. Several mechanisms contribute 
to this antiphagocytic effect. Most importantly, the M protein’s ability to bind 
complement regulatory proteins, the C4b-binding protein and Factor H, interferes 
with the effect of C3b and phagocytosis [34, 152]. Furthermore, the binding of M 
protein to human fibrinogen may sterically interfere with the binding of complement 
protein C3b to the bacterial cell surface [34]. This results in resistance to 
phagocytosis and the complement’s ineffectiveness in direct killing of GAS by 
production of membrane attack complexes on the surface of the pathogen.  
 
Other functions of the M protein contributing to virulence are the adherence to skin 
keratinocytes and involvement in the internalisation and invasion of human cells 
[34]. M protein has also been found to form complexes with fibrinogen, which by 
binding to intergrins on the surface of neutrophils are able to activate the release of 
heparin binding protein, an inflammatory mediator inducing vascular leakage [131]. 
STSS is characterised by excessive plasma leakage and M protein/fibrinogen 
complexes have been identified in tissue biopsies from an NF patient with STSS 
[131]. Furthermore, M protein can interact with human toll-like receptor 2 and 
stimulate monocytes to produce high amounts of proinflammatory cytokines, a 
process that is particularly enhanced by heparin binding protein [249].   
 
Quite recently, a pilus-like structure, containing T antigens of the Lancefield T 
typing system, was recognised on the surface of GAS, indicating that at least some 
of the T proteins constitute a pilus structure [225]. Pili are known to be virulence 
factors in gram-negative bacteria and may serve the same function in GAS [26]. The 
pilus components are members of a family of extracellular matrix-binding proteins 
involved in adhesion and invasion. The variability in the T proteins is also used as a 
basis of serological typing of streptococci (T typing) [224]. 
 
Group A streptococci have several fibronectin-binding surface proteins. One of 
these is protein F1 (PrtF1, also known as SfbI, streptococcal fibronectin binding 
protein I), the expression of which is enhanced in an oxygen-rich environment and 
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thus it is thought to be important for adherence to mucosal or skin surfaces and for 
internalisation [34, 126]. A homologous protein has been identified in group G 
streptococcus (GGS), indicating that a horizontal transfer of genes has taken place 
between group A and G streptococci [320]. The serum opacity factor (SOF, OF) is a 
streptococcal surface protein that binds to fibronectin and fibrinogen, and 
contributes to the pathogenesis of GAS by promoting invasion to human epithelial 
cells [61, 318].  
 
Several extracellular secreted proteins also contribute to virulence. Secreted 
deoxyribonucleases (DNases) A, B, C, and D, enzymatically participate in the 
degradation of DNA, possibly facilitating the spread of streptococci through tissues 
[34]. An extracellular DNase also protects from phagocytosis and thus enhances the 
evasion from human immune functions [302]. The streptokinase enzyme is produced 
by all strains of GAS and proteolytically converts plasminogen to active plasmin, a 
process that contributes to the dissolution of clots [34]. A hyaluronidase enzyme is 
able to degrade hyaluronic acid in human connective tissue [34]. Yet another 
protein, a C5a peptidase, specifically cleaves the human chemotaxin C5a, inhibiting 
chemotaxis and preventing phagocytosis. Many invasive GAS strains also express a 
nicotine-adenine-dinucleotidase (NADase), but its function in pathogenesis is not 
known [294].  
 
Some secreted proteins work against the complement’s function. Streptococcal 
inhibitor of complement (Sic) is produced predominantly by M1 strains and it 
inhibits the function of the complement membrane attack complex and prevents the 
bacterial cell from lysing [106]. Sic also interacts with a protein ezrin that is located 
in the eukaryotic plasma membrane and inhibits the human polymorphonuclear cells 
from internalising the microbe, enhancing the pathogen’s survival [138]. The sic 
gene coding for the Sic protein is located in the Mga regulon near the emm gene [4]. 
Sic is a highly variable protein and there is evidence that Sic variants are being 
selected on the human mucosal surface [139].  
 
Toxins have a critical role in streptococcal pathogenesis by contributing to the 
severity of infection [177, 234]. Secreted toxins and enzymes facilitate pathogenesis 
and invasion to tissues. Two distinct haemolysins have been found: streptolysin O 
(SLO) and streptolysin S (SLS), which cause β-haemolysis of blood. SLO is a pore-
forming cytolysin which has toxic effects on a variety of cells and is able to induce 
apoptosis of macrophages [319]. SLO is antigenic and produced by almost all GAS 
strains as well as by some group C and G strains [34]. SLS is one of the most potent 
cytotoxins inhibited by phospholipids, such as serum lipoproteins. SLS and SLO are 
both able to mediate damage to the membranes of polymorphonuclear leukocytes 
[34].  
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The streptococcal superantigens (SAgs) are able to induce potent inflammatory 
responses [177]. The SAgs are the streptococcal pyrogenic exotoxins (Spes) A, C, 
G-M, the streptococcal superantigen (SSA) and the streptococcal mitogenic exotoxin 
SmeZ [60]. Normally, antigens are processed into small peptides by the antigen 
presenting cells and displayed on the surface of these cells bound as complexes to 
major histocompatibility complex (MHC) class II molecules. The MHC-peptide 
complexes are then recognised by T cells via T cell receptors (TCR), which induces 
T cell activation and leads to the release of inflammatory cytokines. However, 
superantigens are able to induce T cell activation without prior processing in the 
antigen presenting cells by binding directly to MCH class II molecules and TCRs 
outside the antigenic binding site [130, 177]. The binding is not dependent on the 
antigen specificity of the T cell, and SAgs may stimulate as many as 20% of all T 
cells, whereas the binding of conventional antigens activates approximately 0.01% 
of T cells. SAgs are believed to have a critical role in NF and STSS [34, 177, 239]. 
The excessive proliferation of T cells and the subsequent massive release of pro-
inflammatory cytokines and interleukins is believed to lead to capillary leak, and to 
be responsible for the most severe consequences as seen in STSS: hypotension, 
shock, multi-organ failure, and death [1, 292]. The lack of protective anti-SAg 
antibodies has been found to be associated with an increased risk for developing 
STSS [15, 97]. 
 
The distribution of the streptococcal SAgs varies among strains [11]. There are three 
chromosomally encoded (speG, speJ and smeZ) and eight prophage associated 
(speA, speC, speH, speI, speK/L, speL/M, speM and ssa) superantigen genes [201, 
231]. Some of the streptococcal superantigens have homology to staphylococcal 
superantigens, indicating a horizontal transfer from S. aureus [253]. The SpeA 
exotoxin has been associated with severe scarlet fever cases [294]. There is strong 
support to the hypothesis of SpeA enhancing the persistence of GAS in natural 
populations [21]. Strains harbouring speA and/or smeZ genes are potentially 
involved with severe disease and STSS [22, 97, 201, 230, 254, 295]. SmeZ exhibits 
the highest allelic variation of SAgs and especially its variant SmeZ-2 is the most 
potent superantigen [253]. The majority of strains seem to harbour speG gene [72, 
90, 198]. There is evidence for identical or nearly identical SAg genes of speM, ssa, 
and smeZ existing in S. dysgalactiae subsp. equisimilis and S. canis strains, 
suggesting a frequent interspecies gene exchange between these species and S. 
pyogenes [149, 163]. 
 
The gene encoding SpeB is present in virtually all GAS strains, but its expression 
varies greatly from strain to strain [294]. Although SpeB was initially believed to be 
a superantigen, its toxic potential may be solely due to its cysteine protease activity 
[34]. SpeB contributes to pathogenesis in several ways, resulting from its ability to 
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cleave a variety of host proteins, such as immunoglobulins, vitronectin, and 
fibronectin, and to induce the release of biologically active peptides which promote 
the pathogen’s ability to spread through tissues [34]. Similarly, SpeF toxin is not a 
superantigen but a streptococcal DNase [253].  
 
Novel streptococcal superantigens are continuously being found. The fact that M1 
serotype strains are overrepresented in STSS has inspired researchers to investigate 
these strains in more detail. There is recent evidence that a soluble M1 protein is 
actually a novel streptococcal superantigen [248]. It remains to be seen if this is a 
unique property of the M1 protein, as the distinct M proteins do share high 
homology with each other at a structural level.  
 
Although certain SAg profiles are found more frequently among invasive isolates, 
no clear association has been found between pathogenicity and the presence of 
single SAg genes [49, 72]. However, pharyngeal isolates may harbour SpeA and 
SpeC genes more often than the invasive isolates [128]. Superantigen genes are not 
randomly distributed among GAS isolates, but have been found to associate with 
particular M/emm types [60]. However, the occurrence of SpeA in isolates of the 
same M type varies depending on the geographic region [50, 228, 233]. Several 
toxin-gene profiles can be identified within a single emm type, but mostly 1-2 toxin-
gene profiles dominate, indicating that a few successful invasive clones have spread 
throughout the world [268]. 
 
One important factor contributing to the pathogenesis and host adaptation is the 
allelic variation of genes encoding virulence factors, as many of the GAS virulence 
genes are polymorphic [257]. The regulation of gene expression is also likely to 
contribute to GAS survival. A recent functional analysis showed that a very 
effective adaptative metabolic shift occurs within 30 minutes of bacterial exposure 
to human blood, manifested by the increased transcription of genes encoding for 
superantigens and host-evasion proteins [118]. The first virulence network that was 
described in GAS was the Mga, the multiple gene regulator of GAS. The Mga-
regulated genes encode, in addition to the M protein and M-like proteins, the 
streptococcal collagen-like protein, the SOF, the C5a peptidase, and Sic, among 
others [64, 258]. There is suggestive evidence that the Mga-regulated products are 
required in adhesion, internalisation, and immune evasion, in other words, during 
entry of GAS into new tissue sites [180, 212].  
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2.2.5 The GAS genome 
The group A streptococcal genome is a single circular chromosome, approximately 
1.9 Mb in size. Approximately 10% of the genome consists of variable regions, 
including prophage-like elements or their remnants and insertion elements, for 
which prophages may be the primary source [11]. The rest, roughly 90% of the 
genome, is called the “core genome”, which is the part of the genome not including 
prophage-like and obvious insertion elements. The core genome encodes for many 
proven or putative virulence factors such as M protein, streptolysin O, streptolysin 
S, streptococcal cysteine protease, and the hyaluronic acid capsule [20]. 
 
GAS is unique among the bacterial species so far sequenced in the magnitude to 
which the phages account for genome diversification and variation of gene content. 
Acquisition and loss of prophages generates distinct genotypes with novel 
combinations of virulence factor genes [22]. Most of the SAg genes are associated 
with the prophage sequences, except for speG, speJ, and smeZ, which are encoded 
by the core genome [253]. The prophage elements and virulence genes can be 
horizontally transferred between strains of GAS and also between different 
streptococcal species, which may lead to clones with enhanced potential for 
pathogenesis [5, 75, 164]. 
 
At present, the genome of 13 GAS strains of 10 M types have been sequenced 
(Table 3) and more genomic sequences are in progress according to information 
from NCBI (National Center for Biotechnology Information) GenBank [21, 217, 
232]. The size of the sequenced genomes varies from 1.815,783-1.937,111 bp 
depending on the strain. The sequenced genomes are not closely related to each 
other but have been selected for their properties, e.g. M type, virulence or source of 
isolation. All of the sequenced strains are polylysogenic (including multiple 
prophages) and the prophages constitute the primary source of variation in these 
strains [11]. Each prophage encodes for 1-2 virulence factors.  
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Table 3. The sequenced Streptococcus pyogenes genomes. Adapted from [21, 217].  
Strain M type
 
No. of 
pro-
phages 
GenBank 
accession no.
Information on the strain, 
association with disease 
Reference 
SF370 M1 4 AE004092 wound infection [107] 
MGAS5005 M1 3 CP000017 cerebrospinal fluid (Canada) [301] 
MGAS10270 M2 5 CP000260 pharyngitis (USA) [20, 21] 
MGAS315 M3 6 AE14074 STSS, high virulence (USA) [23] 
SSI-1 M3 6 BA000034 STSS (Japan) [231] 
MGAS10750 M4 4 CP000262 pharyngitis (USA) [20, 21] 
Manfredo M5 5 AM295007 acute rheumatic fever [141] 
MGAS10394 M6 8 CP000003 pharyngitis, paediatric, 
macrolide- resistant (USA)  
[12] 
MGAS2096 M12 2 CP000261 acute glomerulonephritis 
(Trinidad) 
[20, 21] 
MGAS9429 M12 3 CP000259 pharyngitis, paediatric (USA) [20, 21] 
MGAS8232 M18 5 AE009949 acute rheumatic fever (USA) [288] 
MGAS6180 M28 4 CP000056 invasive infection (USA) [121] 
NZ131 M49 3 CP000829 acute glomerulonephritis 
(New Zealand) 
[217] 
 
Sequencing of the genomes has revealed that variably-present genes are confined to 
few genomic areas, mostly located in the middle of the chromosome, distal to the 
origin of replication. Different GAS strains may include the same foreign genetic 
elements but these may be inserted in different locations in the genomes, which adds 
complexity to the genomic research of streptococci [21]. Considerable variation 
exists in the prophage content and prophage-associated virulence factors among 
strains of the same M type, in other words, strains of the same M type are not 
clonally related [11, 21, 23, 22, 122, 121, 301]. emm28 isolates have been shown to 
have considerable diversity in the prophage-associated virulence gene content, as 
compared to emm1 isolates, the majority of which are thought to be descendants of a 
virulent clone that emerged and became abundant during the 1980s [98, 122, 301].   
 
In addition to prophage sequences, unique genetic material encoded by integrated 
conjugative elements (ICEs), which may influence the fitness or survival properties 
of the pathogen, has recently been found in the GAS genome [217]. The known and 
putative virulence factors associated to non-bacteriophage related genes have been 
found to be restricted to 11 genomic loci which are generally accompanied by 
mobile genetic elements [213]. Profiling of these loci could be a useful typing tool 
in epidemiological studies of GAS.  
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Sequencing of the type M28 genome has given new insight into puerperal sepsis. A 
non-prophage region of 37.2 kbp in size and encoding for seven inferred 
extracellular proteins seems to be present in all M28 strains. Interestingly, RD2 has 
a similar composition and sequence as regions of certain serotypes of group B 
streptococci, the primary causative agent of neonatal infections due to maternal 
epithelial colonisation and transfer during pregnancy or delivery [121, 337]. 
Suggestive evidence points to aquisition of RD2 with horizontal gene transfer from 
GBS to GAS, which could have enhanced the pathogenic potential and niche 
adaptation of the M28 strains, contributing to their overrepresentation in neonatal 
invasive infections and puerperal sepsis [122, 121, 289]. One of the extracellular 
proteins encoded by RD2 is the R28 protein, which promotes the adhesion of GAS 
to human epithelial cells in laboratory studies and possibly also participates in the 
pathogenesis of puerperal sepsis [7].  
 
2.2.6 Characterisation and classification of strains 
The classical serological typing schemes for GAS are based on the variability of 
antigenic surface-exposed proteins, such as the T protein, the serum opacity factor 
protein, and the M protein. T serotyping, based on agglutination of the T antigen 
with type-specific sera, identifies approximately 25 distinct T types. It was 
introduced in 1965 and has been widely used for the characterisation of strains 
[224]. A characteristic of T typing is that it results in complex agglutination patterns 
due to strains harbouring several T protein antigens [156, 159]. The function of the 
T protein as a pilus-like structure, contributing to the virulence of the bacterium, was 
discovered only recently [225]. Sequence variation of the pilus backbone variant, tee 
sequence typing, has been proposed as a molecular typing tool to substitute for the 
serological T typing [104]. Detection of the presence of the SOF protein and its 
specific type has also been used for typing purposes of GAS and it has provided a 
useful tool for initial screening and characterisation of GAS, especially when 
combined with T typing [207].  
 
Serologic M typing, originally introduced by Dr. Rebecca Lancefield, is based on 
variation in the streptococcal M protein [187]. With this method, still in use in some 
countries, GAS can be classified into 80 serotypes by the difference in the 
hypervariable N-terminus of the M protein (see also Figure 1 in section 2.2.4). 
Because specific M, T, and OF types correlate with each other and some type 
combinations have been associated with certain clinical manifestations and severity 
of disease, these methods have been used in unison to obtain more specific 
information on the diversity of strains [19, 72, 99, 156, 159]. Common problems 
encountered with serological typing methods are limitations in the specificity and 
availability of typing antisera, leading to ambiguous results and a large number of 
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nontypable isolates. Conventional methods are therefore being replaced with, or 
strengthened by, the use of molecular methods.  
 
The first alternatives to serological M typing were PCR-based methods with probes 
directed to recognise different types of M-protein in a method called M-ELISA 
typing, based on an enzyme-linked immunosorbent assay [174, 250, 252, 267]. 
Recently, emm (sequence) typing, based on sequencing a 180 bp portion of the 
hypervariable 5’ terminus of the emm gene, has become the ‘gold standard’ method 
for genotyping of streptococci [17, 88, 100]. In addition to the designation of emm 
types to the the original serologic M types up to M81, new emm types of 82-124 
have been validated and added accordingly [100, 101]. At present, well over a 
hundred emm sequence types and a far higher number of subtypes have been 
identified and stored at the Streptococcus pyogenes emm sequence database at the 
Centers for Disease Control and Prevention (CDC) [45, 101]. The emm typing 
results are accurate, unambiguous, and easily comparable. emm typing provides 
good discriminatory power of isolates, but for the purpose of investigating the 
clonality of strains, such as in outbreak investigations, emm typing is best when 
complemented by other methods, serological or molecular [18, 19].  
 
Pulsed-field gel electrophoresis (PFGE) targets the whole genome of the bacterium 
and is a widely used typing method for investigating genetic relationships between 
isolates for many bacterial species [283, 313]. The whole bacterial DNA is digested 
with a rare-cutting restriction enzyme (usually SmaI for GAS) to obtain a relatively 
small amount of fragments 20-800 kb in size, which are separated in a specific gel 
electrophoresis apparatus that periodically switches the direction of the electrical 
current, allowing the separation of large DNA fragments. Random genetic events 
such as deletions, insertions, and point mutations sometimes alter the restriction sites 
and affect the restriction pattern of a strain. PFGE has a high discriminatory power 
that can be enhanced by the choice of an appropriate cutting enzyme, and it is most 
useful in epidemiological studies and outbreak investigations. The downside of this 
method is that it is time-consuming and interlaboratory comparison of strain patterns 
is difficult.   
 
Multilocus sequence typing (MLST) is based on sequencing seven highly 
conservative “housekeeping” genes necessary for cell functions and it results in 
distinct allelic profiles called sequence types (ST). The STs are highly concordant 
with other typing methods such as emm typing, but MLST can usually discriminate 
two or more STs among isolates of a single emm type [44, 93]. MLST is 
considerably expensive and laborious, but its advantages are easy comparison of 
allelic profiles between laboratories and the unambiguous numerical form of data. 
An MLST database for several bacterial species is available in the internet [222]. 
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When performed coupled with emm typing, either MLST or PFGE provide more 
discriminatory power and benefit to clonal analyses than is possible to obtain by 
emm typing alone [44]. 
 
Other genomic typing methods that have been used for characterisation of GAS are 
restriction endonuclease analysis (REA) typing and fluorescent amplified-fragment 
length polymorphism analysis [78, 79, 274]. Some typing methods are restricted to 
specific genomic areas or genes. Vir typing was developed before emm typing; it is a 
restriction fragment length polymorphism (RFLP) analysis of the pathogenicity 
island encoding emm and other virulence genes [113]. Sequence analysis of the 
hypervariable sic gene coding for the streptococcal inhibitor of complement protein 
has also been used for clonal analysis of M1 isolates in more detail. This method is 
very effective in discriminating distinct clones, as the sic gene polymorphism is 
extensive, but its use is naturally restricted to strains harbouring the sic gene [136, 
297]. Ribotyping is based on the analysis of polymorphisms of 16S rRNA genes and 
has been used to characterise bacterial isolates of many species, but may lack 
discriminatory power compared to MLST [81, 290].  
 
The oligonucleotide microarray is a novel technology that has been used for efficient 
and accurate detection of GAS with the additional benefit of identifying 
erythromycin resistance markers [76]. This technology offers promising possibilities 
for diagnostic and genotyping purposes, as it could be expanded to cover a wide 
array of genes, such as additional antimicrobial resistance genes, the emm gene, and 
SAg genes.  
 
2.3 The epidemiology of S. pyogenes infections  
Throughout the 20th century, the prevalence of rheumatic fever and other severe 
infections by GAS declined dramatically in developed countries [167, 206]. One 
reason for this decline was the development and availability of antimicrobial agents 
[77]. Other probable reasons include the improved socio-economic conditions, 
application of aseptic techniques, and a decreased prevalence of virulent strains 
[115, 173]. For several decades until the mid-1980s, the morbidity and mortality due 
to GAS infections and their sequelae was quite low and consequently the GAS 
infections were not often considered to be serious [88, 157].  
 
However, during the latter half of 1980s and continuing into the 1990s, a change in 
the epidemiology of invasive group A streptococcal infections, with an increase in 
the incidence as well as severity of disease, was documented in many developed 
countries [42, 88, 115, 140, 157, 270, 295]. Cases presented with a range of diseases 
including bacteraemia, necrotizing fasciitis and toxic shock [53, 295]. A high 
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prevalence of strains producing SpeA toxin was noted [53, 295]. Simultaneously, the 
incidence of acute rheumatic fever increased in the USA, although this was later 
discovered to be only a temporary increase with ARF later practically disappearing 
in the USA [167, 278, 326, 327]. Indications of an increasing incidence of erysipelas 
infections with the predominant site changing from the face towards the leg were 
also observed [48, 264]. The role and pathogenic potential of type M1, M3 and M18 
in the epidemics was of specific interest, as these types were disproportionately 
associated with invasive infections [53, 59, 157, 204, 270, 300]. Type M18 was also 
found to be associated with acute rheumatic fever [157, 270].   
 
The reasons for the resurgence of the invasive infections are still not fully 
understood. This could have resulted from a change in the pathogen or in the 
protective immunity of the population. A hypothesis prevailed that the emergence of 
highly virulent clones of GAS was the primary explanation behind the surge of 
invasive infections, but no single clone was found to significantly associate with 
invasive infections [158, 263]. A possible role of the population’s lower level of 
immunity towards the invasive types was suggested, but it was unlikely to be the 
leading cause for the resurgence [53, 270]. An event likely to contribute was a shift 
in the prevalence of specific types or strains among GAS with certain virulence 
factors leading to increasing numbers and widespread transmission of these strains 
among the general population at the time [53, 157, 263]. Recent studies point to 
horizontal gene transfer events leading to the evolution of a new, unusually virulent 
clone of type M1 that increased dramatically in frequency since the 1980s [301].  
 
Virulent clones causing invasive disease are indistinguishable from strains causing 
uncomplicated pharyngitis [49, 157, 158, 228]. It is highly probable that the majority 
of patients developing invasive infections are infected through contact with 
individuals, most likely children, with relatively benign infections such as 
pharyngitis, as direct transmission of invasive disease is rare [73, 96, 158]. Thus the 
importance of pharyngitis and pyoderma in leading to not only post-streptococcal 
disease, but also secondary cases of invasive disease, cannot be ignored [43, 125, 
128, 137, 205, 228]. The fact that infections by the same clone of GAS can manifest 
themselves differently depending on the individual, also point to a strong role of 
host factors influencing the outcome of an infection (see also section 2.5) [49].   
 
Although the risk of a subsequent iGAS case after transmission of the pathogen from 
the patient to another person is higher than the risk of iGAS disease among the general 
population, the risk is considered low and routinely administered chemoprophylaxis is 
not recommended [262, 286]. The suggested alternative action is to inform all 
household contacts of the clinical manifestations of invasive disease and to advise 
them to seek immediate medical attention if such symptoms arise [286]. 
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2.3.1 Estimates of overall disease incidence 
Severe S. pyogenes infections are not notifiable diseases in many countries. The 
methods, criteria, and coverage of severe GAS disease surveillance vary 
considerably by country and may depend on voluntary reporting systems [182]. 
Some countries include only bacteraemia and cerebrospinal fluid (CSF) isolations 
whereas in some countries the case definition of severe iGAS disease is wider, 
including also isolations from other normally sterile sites and STSS cases without 
bacteraemia. For this reason, the comparison of disease rates between countries is 
challenging and relatively few population-based studies with results from several 
consecutive years exist.  
 
The Strep-EURO-network was set up in 2002 and aimed at improving knowledge of 
the epidemiology of iGAS and unifying the surveillance strategies used for severe 
GAS disease in Europe [182, 185]. This collaboration involved collection of 
epidemiological, clinical, and microbiological data. Since the resurgence of GAS 
infections, there has been a general view of an increasing incidence of invasive 
disease during the 1990s and 2000s in many European countries [182]. In the Strep-
EURO study, Finland, Denmark, Sweden, and the UK had the highest rates of 
infection (range 2.5-3.3 cases per 100,000) during 2003-2004 in Europe [185].  
 
The European findings are somewhat in contrast to the situation outside Europe. The 
incidence in the USA has remained relatively stably at an average rate of 3.5 cases 
per 100,000 during 1995-2004 [242, 244]. The statistics from the Active Bacterial 
Core Surveillance show a moderate increase recently, with a rate of approximately 
3.8 per 100,000 in 2007 [46]. Studies from Canada showed a steady rate in the range 
of 2.4-3.3 cases per 100,000 during 1998-2001 in Montreal but higher rates of 4.3 
during 1999-2004 in Calgary and 3.8-5.7 during 2000-2002 in Alberta [143, 188, 
322]. In temperate Australia, Victoria, a rate of 2.7 cases per 100,000 during 2002-
2004 was reported [243].  
 
The incidence rates in developed countries within and outside Europe are at a 
relatively similar level. The fluctuation in incidence is characteristic for this disease, 
as variations and occasional peaks occur over time and within defined geographical 
regions [185, 244, 322]. This is possibly a reflection of the susceptibility of a given 
population to particular strains with diverse virulence properties. Nonetheless, the 
estimates of incidence of iGAS disease in developing countries such as Fiji and 
Kenya and among the indigenous populations within developed countries such as 
Australia and New Zealand have shown considerably higher rates of infection [25, 
140, 241, 291].   
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GAS is an important cause of morbidity and mortality, mainly in less developed 
countries [43]. The global disease burden of severe GAS diseases is considerable: a 
report by the WHO estimated that currently approximately 18.1 million people 
experience the consequences of a severe GAS infection, with 1.78 million new cases  
occurring each year [43]. Among these, at least 663,000 new cases of invasive 
disease and 163,000 deaths occur each year [43]. In reality, the true disease burden 
could be much greater.  
 
2.3.2 Age- and sex-specific rates of infection 
There are certain characteristics in the age-specific rates of infection that are 
commonly observed. Children under 5 years of age and the elderly (≥65 years) 
generally have a higher incidence of iGAS disease compared to other age groups 
[72, 185, 198, 322]. The incidence rate in children aged <5 years has been at a level 
of 2 or less cases per 100,000 in Scandinavian countries of Sweden and Denmark 
[72, 198], which is lower than is observed in the UK, the USA, Canada and 
Australia [185, 243, 244, 322]. A slight male dominance in iGAS infections has 
been noticed in several studies [185, 188, 243, 244], but also some contrasting 
findings have been published [72, 90]. 
 
2.3.3 Mortality associated with invasive infections 
The WHO estimate of 163,000 deaths occurring globally each year due to iGAS 
infections is likely to be an underestimate, because data from many developing 
countries are unavailable [43]. The overall case fatality rates due to iGAS infections 
as reported by countries within and outside the Europe vary in the range of 7-25% 
[72, 90, 184, 198, 243, 244, 322]. The case fatality is dependent on the streptococcal 
M type (especially types 1 and 3 have been associated with higher case fatality), age 
of the patient (the rate increasing with age), and whether the infection is associated 
with necrotizing fasciitis (higher case fatality of 17-45%) or if the patient develops 
STSS (23-81%, respectively) [72, 73, 90, 96, 185, 196, 241, 242]. Residents of long-
term care facilities have a higher incidence and case fatality rates due to iGAS 
infections than community-based case-patients [315].  
 
Differences in the case fatality rates are also subject to what information is available. 
The case fatality rate can be presented as deaths within 7 or 30 days after the onset 
of infection, or outcome at the time of hospital discharge, or some other measure. 
Further, the rates are subject to bias in the reporting system, since with non-
automatic reporting systems and the coverage of surveillance being less than 100%, 
it is possible that the more severe cases are more likely to be reported than the 
milder cases.  
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2.3.4 Clinical presentations 
There are quite a few recent epidemiological studies published in Europe (Sweden, 
Denmark, the Netherlands, the UK) and outside Europe (the USA, Canada and 
Australia), including detailed information of clinical presentations of iGAS disease 
[72, 90, 185, 184, 198, 242-244, 300, 322, 333]. The individual studies differ 
somewhat from each other in the criteria used for defining some of the clinical 
presentations. Many patients may also have more than one clinical presentation, i.e. 
the data are overlapping. The ranges of percentages for each clinical presentation 
presented next are compiled from these studies.  
 
The most common manifestations of severe S. pyogenes infections are skin and soft 
tissue infections (including most importantly cellulitis, but may also include 
necrotizing fasciitis, abscess, and erysipelas). These infections usually account for a 
range of 20-40% of the cases but in some studies more than 50%, depending on how 
broad the definition of skin and soft tissue infections is, but also on geographical 
differences in the epidemiology of these infections. However, quite commonly, 12-
30% of the patients with a severe S. pyogenes infection have bacteraemia with no 
focal symptoms or source. Other commonly reported individual clinical 
presentations in the order of prevalence are pneumonia (10-15%), septic arthritis (5-
15%), necrotizing fasciitis (5-13%), STSS (6-11%), puerperal sepsis (2-7%), and 
meningitis (1-4%). Most iGAS cases arise in the community; according to some 
epidemiological studies, 4-13% of iGAS infections are healthcare-associated 
(hospital-acquired) [71, 182, 185]. 
 
2.3.5 Trends in emm type prevalence 
Certain emm types feature regularly among the most prevalent types causing 
invasive infections in developed countries, in particular 1, 3, 12, 28, and 89 [72, 90, 
135, 195, 200, 198, 243, 244, 323]. The five most prevalent types may account for 
approximately 50% or more of the total amount of isolates [198, 242, 244]. Table 4 
lists a comparison of epidemiologic studies of iGAS with emm type information 
published in the 2000s. The results of these and earlier studies point out that the 
prevalence of specific GAS types, both in mild and severe infections, shows high 
variability over time and geographical area [72, 168, 242, 268, 280]. In any given 
population, a continuous flux of common and sometimes uncommon emm types 
seem to emerge and replace the prevalent types. Thus, the prevalence of certain 
types in invasive or noninvasive infections is a reflection of the circulating types of 
S. pyogenes in the general population at a given time.  
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There are some studies of the emm type distribution in developing countries and 
countries from which there is no previous information, such as Ethiopia, India, Fiji, 
and Brazil, where the diversity of types may be larger and the type distribution 
different compared to that of European countries or the USA [2, 80, 266, 291, 312, 
314].     
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2.3.6 Association of emm type and disease manifestation  
Epidemiological studies have shown the existence of non-random associations of M 
types to particular infections [115, 195, 242, 323]. Types M1 and M3 are 
particularly associated with invasive and fatal infections (and also with STSS) but 
are also common in pharyngeal infections [59, 72, 157]. Similarly, M28 is 
commonly found among invasive and pharyngeal infections, but also significantly 
overrepresented among puerperal sepsis and neonatal GAS infections [51, 59, 72, 
98, 121]. In addition to the aforementioned types, especially type M12 has been 
encountered as the most prevalent type among non-invasive pharyngeal isolates but 
it is not uncommon in invasive disease either [72, 157, 278, 280, 309]. 
 
The so-called rheumatic M types particularly associated with acute rheumatic fever 
are 1, 3, 5, 6, 18, 19, and 24; also types 14, 27, and 29 have been known to cause 
ARF [59, 157, 278, 298]. The most important M serotypes associated with acute 
poststreptococcal glomerulonephritis (the nephritogenic types) are 49, 57, and 60 
[59, 157, 217]. M80 and M81 have been known to be more common in pyoderma 
and are more frequently encountered in infections that involve the skin and tissues 
[59, 72].  
 
Isolates of a single emm type may represent a wide array of distinct strains, which 
may greatly differ in their genetics, virulence potential or epidemiological 
characteristics [211]. Indeed, the genetic diversity of adhesive molecules may reflect 
the types of diseases caused by GAS [21]. It is also important to keep in mind that 
the associations between the emm type and clinical and epidemiological properties 
of GAS that are observed in one geographic region are not necessarily applicable in 
other parts of the world [211]. 
 
2.3.7 Factors predisposing to invasive S. pyogenes infections  
Several host and environmental factors have been identified as predisposing factors 
to S. pyogenes infections, and they have a potential role in the severity and outcome 
of infection [73]. Age is an important host factor and certain age groups are at a 
higher risk of developing invasive disease, such as small children and especially the 
elderly. For both adults and children, household overcrowding and exposure to 
children with sore throat have been found to increase the risk of infection [103]. 
Common risk factors for adults also include underlying diseases such as cardiac 
disease, cancer (with local radiation therapy causing tissue damage), and diabetes 
[73, 102, 198, 242-244, 304]. Specific risk behaviours, such as alcoholism and 
injecting drug use, are also associated with the increased risk of invasive infection 
[73, 102, 184, 242, 244]. Skin conditions (burns, trauma, and surgical wounds) 
understandably predispose to infections [244]. A viral infection, such as a varicella-
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zoster virus (causing chickenpox) or HIV, has also been identified as a risk factor 
[73, 102, 189, 243]. Institutional acquisition (iGAS aquired in a hospital, nursing 
home or long-term care facility) is a common risk factor [198, 315, 322]. Yet, 
approximately 17-20% of patients with iGAS infection have no predisposing factors 
[185, 242].  
 
2.3.8 Seasonal variation 
One feature of S. pyogenes infections as identified in many countries is a seasonal 
variation in the number of cases. In Europe, such as the UK, Sweden, and the 
Netherlands, as well as in the USA and Canada, a peak of invasive cases has been 
observed in winter/spring months, with a lower incidence in late summer/autumn 
[72, 73, 185, 244, 322, 334]. Similar to invasive infections caused by S. pyogenes, 
streptococcal pharyngitis shows a seasonal pattern towards the autumn and winter, 
whereas skin related infections have been found to be more prevalent during the 
summer [64, 91, 223, 264].  
 
The reasons for seasonal variation are not clear but several factors may have a role: 
environmental changes (humidity or temperature) affecting the mucosal defence 
barriers, behavioural patterns such as crowding of susceptible persons as a result of 
cold weather or school seasons, changes in susceptibility of the human host 
associated to the annual light/dark cycle, or viral respiratory infections inducing 
vulnerability to S. pyogenes infection [82, 83, 185]. Increased exposure of skin to 
superficial trauma during the summer, as well as a delayed wound healing, may 
contribute to the seasonal variation for skin and soft tissue infections such as 
cellulitis [264].  
 
2.4 Preventive measures and treatment 
2.4.1 Antimicrobial resistance and treatment strategies 
Antimicrobial resistance is a common problem worldwide and the consumption of 
antimicrobials has been identified as a driving force for the emergence and 
transmission of antimicrobial resistance in bacteria. Group A streptococci are 
sensitive to penicillin and other β-lactam antimicrobials, such as cephalosporins and 
carbapenems [294]. Penicillin is therefore the first drug of choice for treating 
pharyngeal and other streptococcal infections [171]. The continuing susceptibility of 
S. pyogenes to penicillin is remarkable and possibly due to a limited ability to aquire 
foreign DNA and a lower fitness that may be associated with β-lactam resistance 
[146]. Resistance to sulfonamides and tetracyclines in group A streptococci has been 
decscribed already in the mid-1960s [294]. The development of antimicrobial 
2  Review of the literature 
THL – Research 23/2009 42 
 
Molecular and epidemiological aspects of 
Streptococcus pyogenes disease in Finland: Severe 
infections and bacterial, non-necrotizing cellulitis 
 
 
resistance among other bacterial species warrants continuous monitoring to guide 
the appropriate antimicrobial therapy and vaccine development strategies [260].  
 
The potential for increased resistance to erythromycin and other macrolides, as a 
consequence of the widespread use of macrolide antimicrobials, has been widely 
studied [276, 294]. There are two main mechanisms of erythromycin resistance in 
GAS. Firstly, the resistance can be acquired by target site modification; a methylase 
encoded by one of several types of erm (erythromycin resistance methylase) genes 
causes a conformational change in the bacterial ribosome, which is the target of 
erythromycin [192]. This kind of resistance can be constitutive (cMLS phenotype; 
ermB gene) with a continuous production of the methylase enzyme, or inducible 
(iMLS phenotype; ermA gene) when the production of the enzyme occurs only in 
the presence of an inducing antimicrobial [273]. A newly discovered ermTR 
resistance methylase gene was found to be predominant in Finnish S. pyogenes 
isolates and was found mainly in isolates with the inducible phenotype [170]. A 
second resistance mechanism is based on active macrolide efflux by the presence of 
a membrane-associated pump mechanism encoded by the mefA gene (the M 
phenotype) [193]. The constitutive phenotype is manifested in double-disk diffusion 
tests by resistance to both erythromycin and clindamycin, while the inducible 
phenotype is shown by erythromycin resistance and lowered susceptibility to 
clindamycin induced by the proximity of erythromycin disk. Isolates with the M 
phenotype are erythromycin resistant and clindamycin susceptible [170].  
 
High or increasing prevalence of macrolide resistant S. pyogenes isolates has been 
identified in many countries, such as Italy, Spain, Portugal, France, and Japan, and 
lately in Asian countries, such as China, Taiwan, and South Korea [6, 29, 63, 119, 
155, 166, 208, 220, 281, 324, 325]. Spain and Germany, among other countries, 
have had a few prevalent erythromycin-resistant clones which have been the main 
reason for increased resistance [6, 251, 259]. In France, the emergence of clonally 
related multiresistant emm28 isolates was noted in the early 2000s [221]. In Finland, 
an increase of erythromycin resistance of S. pyogenes with new resistance phenotype 
was recognised in the early 1990s, but after restrictions in the use of macrolides, the 
resistance steadily decreased [24, 172, 275, 276, 272]. Countries such as Australia, 
the USA, and Denmark have recently seen a reasonably low level of macrolide 
resistance with moderate or no increase of resistant strains [198, 243, 260]. 
Contrastingly, Romania, Israel, and Iran have had a high rate of tetracycline resistant 
strains with an absence of erythromycin resistance [154, 199, 261, 328].   
 
In Finland, the recommended antimicrobial treatment for streptococcal pharyngitis 
as the first choice is oral penicillin V three times a day for 10 days, and for patients 
with penicillin allergy, a first generation cephalosporin (such as cephalexin) as the 
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second choice [86]. The recommended antimicrobial treatment for streptococcal 
cellulitis is penicillin administered either intravenously or intramuscularly, and after 
the recovery has started, usually after 3-5 days, perorally for a total of three weeks 
[85]. For patients who are penicillin-allergic, cephalosporins are recommended, or, 
alternatively, clindamycin in cases with severe penicillin allergy. In patients with 
blood culture positive GAS finding, the first-line antimicrobial agent is either 
intravenous penicillin G or a cephalosporin [84].  
 
Pooled human immunoglobulin G (IVIG) and polyspecific immunoglobulin IgM, 
IgA, and IgG preparations may have beneficial effects in the treatment of STSS 
[32]. The therapeutic mechanism may at least partly arise through the increasing 
level of M1-specific antibodies, which help in the elimination of bacteria and in 
toxin neutralisation [14, 235, 238, 237]. Despite availability of treatment, severe 
infections complicated by STSS are associated with a high case fatality rate. 
 
2.4.2 Vaccine candidates 
The search for a vaccine to prevent GAS infections has been ongoing for decades 
and at present, several candidate GAS vaccines are under research and development. 
As mild infections sometimes lead to more severe infections, a vaccine that would 
protect against pharyngeal infections could also theoretically at least partly protect 
against more severe infections [128]. Untreated streptococcal infections leading to 
sequelae are a problem especially in developing countries, which could benefit from 
the use of a vaccine to prevent the primary infections. Bacterial structures that are 
associated with adhesion to host cells, such as lipoteichoic acid, fibronectin binding 
proteins, M protein, and T protein, are natural targets for vaccine development.  
 
The M protein, being a major virulence factor of GAS, has been of specific interest 
in vaccine design [187]. Opsonic antibodies directed against the N-terminal part of 
the M protein are mostly responsible for serotypic immunity, but the exceeding 
number of existing M types poses a problem. Nonetheless, according to 
epidemiological studies made in the USA and elsewhere, the majority of GAS 
infections are caused by a relatively small number of M types [56, 185, 243, 244]. 
Thus, a multivalent M-protein based vaccine including the most prevalent types 
could prevent a considerable proportion of GAS infections within a defined 
population and have a significant impact on the burden of streptococcal diseases [67, 
216]. However, the observation that some epitopes of M proteins can induce 
antibodies that cross-react with human tissue and potentially induce autoimmunity 
has hindered attempts to develop an M protein-based vaccine [10, 40, 68, 69, 245]. 
A safe and effective vaccine must be capable of inducing broad strain-protective 
antibodies against GAS and clearing the infection without triggering autoimmune 
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responses [245]. Development of several M protein-based vaccines containing only 
the protective epitopes but with no tissue cross-reactive epitopes is underway.  
 
Among the multivalent M protein-based vaccines, the first one to go into phase I 
clinical trials was a hexavalent recombinant fusion protein peptide containing N-
terminal M protein fragments from serotypes 1, 3, 5, 6, 19, and 24 [66, 179]. The 
second generation M protein-based recombinant vaccine contained 26 M types and a 
newly found streptococcal protective antigen (Spa) [67, 70, 147, 216]. The vaccine 
includes epitopes from M types 1.0, 1.2, 2, 3, 5, 6, 11, 12, 14, 18, 19, 22, 24, 28, 29, 
33, 43, 59, 75, 76, 77, 89, 92, 94, 101, and 114. These M types have been selected 
on the basis of being epidemiologically significant; they are commonly responsible 
for serious infections or uncomplicated pharyngitis in children or are associated with 
ARF [216]. The 26-valent vaccine candidate has undergone phase I and II clinical 
trials with promising results which warrant studies in adolescents and children, who 
are the target population for this vaccine [67, 216, 215]. The downside of this 
vaccine candidate is that it may not be effective in preventing infections within other 
populations such as developing countries, where the diversity of GAS M types may 
be very different [2, 80]. The vaccine may also need re-evaluating and redesigning 
to accommodate future changes in type prevalence among the original target 
population.  
 
A different approach is a vaccine containing epitopes from the more conserved C-
repeat region of M protein [16, 285, 335]. This kind of vaccine would potentially 
protect against a broader spectrum of GAS emm types and its coverage would not be 
dependent on the M type distribution of a given geographical area. Synthetic multi-
epitope vaccines combining N- and C- terminal epitopes are also being investigated 
[39].  
 
Selection of the appropriate adjuvant and carrier systems are essential for effective 
vaccine delivery. Several carrier molecules have been considered for conjugates of 
vaccine antigens, such as synthetic carbohydrates, diphtheria toxoid protein, and 
glycolipids attached to peptide antigens to form lipid-core peptides, the latter of 
which seem particularly promising for possible mucosal administration [16, 112, 
246, 282]. Mucosal vaccines are easy to administer and offer advantages over 
classical parenteral immunisation, with the possibility to induce both systemic and 
mucosal immune responses and thus provide enhanced protection against 
pharyngeal GAS infections [245]. One could expect a significant benefit from a 
mucosal immune response in the prevention of pharyngitis, as mucosal IgA would 
have the potential to attach to pathogens and prevent them from adhering to the 
mucosal epithelium [303, 321].  
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2.5 Susceptibility to streptococcal infections 
Despite the extensive studies aimed at understanding the virulence properties of 
streptococci, the key question remains: Why do some individuals develop a severe 
disease while others only suffer a mild pharyngitis? Human genetic variation is a 
key element in infectious disease susceptibility, as it determines the quality and 
strength of individual immunological responses that have a role in the severity and 
outcome of infections [132]. It is not surprising that the most numerous and diverse 
genes in the human genome are indeed genes involved in the immune response, 
having evolved under selective pressure by infectious agents [111, 229]. Specific 
genes that have a role in the innate immunity, such as the family of pathogen pattern 
recognizing receptors and their associated signalling pathways, have been subject to 
most extensive research in this aspect. Evidence of host genetic factors playing a 
role in the susceptibility to infectious diseases has already been discovered for 
malaria, tuberculosis, and invasive pneumococcal disease, to name a few [36, 132]. 
Based on these and other studies, it is most likely that the genetic basis of 
susceptibility to streptococcal diseases is not monogenic (due to one gene only) but 
polygenic with many minor contributory loci [111, 132]. Given the large number of 
factors contributing to host defence against GAS infections, identification of 
individual genes remains a difficult challenge. 
 
The lack of protective neutralizing antibodies against the M proteins and possibly to 
other virulence factors seems to be a risk factor for developing severe disease [15, 
97, 144, 292]. Furthermore, the lack of protective anti-SAg antibodies has been 
found to be associated with the increased risk for developing STSS [15, 97]. 
However, the quality of the protective anti-Spe antibodies (as measured by the 
neutralizing activity), rather than the quantity of them, is a more important 
determinant in disease pathogenesis [15]. Thus, previous contact with the pathogen 
would help to protect from severe disease, but in case the infection progresses to 
bacteraemia, the course of infection would only partly be determined by host levels 
of antibody to SpeA but also by patient’s age, underlying diseases, and possible 
immunocompromisation [15, 292].  
 
The magnitude of inflammatory responses triggered by superantigens also varies 
considerably by individual. A direct correlation has been found between the 
intensity of inflammatory cytokine response and the severity of the infection [236]. 
Thus variations in genes regulating the inflammatory response are of interest. The 
human leukocyte antigen (HLA) class II molecules are receptors for SAgs. Indeed, 
an association between specific HLA class II haplotypes and the outcome of 
invasive GAS infection has been identified, as certain haplotypes conferred 
protection from severe systemic disease by attenuated inflammatory responses to 
SAgs [178].  
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Autoimmunity is also linked to the susceptibility to infection. Increasing evidence 
exists of the role of an autoimmune process in the pathogenesis of acute rheumatic 
fever [124]. The epidemiological data supporting this hypothesis indicate differences 
in familial and racial incidence, with a markedy higher attack rate in individuals who 
have had a previous episode of ARF [30, 52, 202]. Even more importantly, there is 
immunological evidence of ARF patients having hyperimmune responses to 
streptococcal antigens, and that this is associated with certain HLA class II alleles 
[8, 123, 255, 279].  
 
Research on genetic susceptibility to infectious diseases involves genetic studies of 
both the host and the pathogen, and of the functional interactions between the two. 
There are alternatives to studying the genetics of the host, such as linkage and 
association analyses. Large scale genome scans with several hundreds of markers 
(e.g. microsatellites or single nuclear polymorphisms, SNPs) across the genome are 
now routinely performed to obtain data for these analyses. Linkage analyses aim to 
identify the link between certain markers and the presence of the disease in families 
and to pinpoint certain genomic regions of interest. In studies of familial aggregation 
of infectious diseases, it is most important that the disease phenotype is carefully 
defined and its diagnosis is straightforward. Furthermore, the effect of possible 
transmission of the pathogen between the family members has to be taken into 
account. Association analyses compare the allele frequencies of candidate genes 
between those with the disease and control subjects and aim to determine if there is 
statistical difference in the gene frequencies.  
 
Because S. pyogenes is strictly a human pathogen, there are limitations of animal 
models of GAS disease. Despite this obstacle, laboratory mice can be 
experimentally infected with GAS and several murine models of infection have been 
developed to study the pathogenesis of GAS infections and the inflammatory 
reactions in mice [218]. However, results from animal models of disease may not be 
directly applicable to research of human susceptibility. 
 
Genetic studies of the pathogen involve characterising the pathogen with methods of 
choice and looking for association between the disease phenotype and the properties 
of the pathogen [36]. Both human and bacterial genetic research has greatly 
benefited from the availability of rapid and more efficient SNP genotyping methods 
and DNA microarrays [38, 132]. Microarray-based gene expression analysis has also 
been used for analysing changes in gene expression of host cells during GAS 
infection [117].  
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3  AIMS OF THE STUDY 
 
The purpose of this study was to investigate the recent trends in the epidemiology of 
invasive Streptococcus pyogenes infections, molecular properties of invasive 
isolates, and the microbial aetiology of acute bacterial non-necrotizing cellulitis 
infections in Finland.   
 
The specific objectives of this study were:  
 
1. To analyse and compare the T serotype distribution of invasive S. pyogenes 
isolates in Finland to other countries and to further investigate the 
molecular epidemiology and clonality of serotype T28 through emm typing 
(I).  
2. To investigate the molecular properties of isolates of type emm84, a new 
and uncommon type in Finland, and to compare emm84 cases in terms of 
geographical, patient and outcome information to other cases of invasive 
disease (II). 
3. To analyse and compare the epidemiology of invasive S. pyogenes 
infections in Finland to other countries according overall, annual, age- and 
sex-specific incidence rates, seasonal patterns of infection, emm type 
distribution, antimicrobial susceptibility, and overall and type-specific case 
fatality rates (III).  
4. To isolate and characterise β-haemolytic streptococci causing non-
necrotizing cellulitis infections with geno- and serotyping methods through 
a population-based case-control study, compare streptococcal isolates to 
those causing invasive disease and evaluate pharyngeal carriage of β-
haemolytic streptococci in cases, their household members and control 
subjects (IV). 
5. To assess the usability and discriminatory power of different bacterial 
typing methods for determining the clonality of strains for epidemiological 
surveillance and outbreak investigations.  
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4  MATERIALS AND METHODS 
4.1 Invasive S. pyogenes disease  
4.1.1 Surveillance 
In Finland, with a population of 5.3 million, the national healthcare system is 
organised into 20 healthcare districts, with catchment populations ranging from 
58,000 to 1.5 million. The healthcare districts form five tertiary care districts, each 
with a University Hospital in a major city. Since 1995, all clinical microbiology 
laboratories across Finland have mandatorily notified all S. pyogenes (group A 
streptococcus) isolations from blood or cerebrospinal fluid (CSF) to the National 
Infectious Disease Register (NIDR) held by the National Institute for Health and 
Welfare, THL (formerly the National Public Health Institute of Finland) [316]. With 
each notification, the following information regarding the isolation and patient is 
transmitted (generally electronically) to NIDR: date and type of specimen, unique 
national identity code of the patient (since 2004), date of birth, sex, and place of 
treatment. Notifications concerning the same patient within a time interval of three 
months are merged into a single case. The GAS isolates corresponding to the 
notifications are submitted to the national reference laboratory at THL for 
confirmation, typing, and culture collection.  
 
4.1.2 Case definition and outcome 
A case of invasive GAS was defined as S. pyogenes isolated from blood or CSF. 
This study included iGAS cases and the corresponding isolates from January 1995 to 
December 2007. Information on the vital status of the case-patients at 7 days of 
positive blood or CSF culture was obtained for 2004-2007 from the Population 
Information System held by the Population Register Centre through the use of the 
national identity codes.  
 
4.1.3 Collection, culturing and identification of isolates 
Blood and CSF samples were processed by the clinical laboratories of the healthcare 
districts. Isolates of S. pyogenes from all culture positive specimens were sent to 
THL in swab culture tubes. The bacterial isolates were cultured on sheep blood agar 
and incubated in 5% CO2 at 35°C, and bacterial growth was determined at 24 h and 
48 h. Isolates were confirmed as S. pyogenes by β-haemolysis on blood agar, 
sensitivity to bacitracin, and detection of the Lancefield group A antigen by Streptex 
latex agglutination test (Remel Europe Ltd). The isolates were stored for culture 
collection at -70°C.  
  
4  Materials and methods 
THL – Research 23/2009 49 
 
Molecular and epidemiological aspects of 
Streptococcus pyogenes disease in Finland: Severe 
infections and bacterial, non-necrotizing cellulitis 
 
 
4.1.4 Review of patient medical records 
A cluster of invasive infections by type emm84 occurring within one hospital in one 
healthcare district was investigated in more detail (publication II). Patient medical 
records were reviewed in order to identify underlying conditions and if the patients 
had had any common exposure or contact with each other. 
 
4.2 Acute streptococcal non-necrotizing cellulitis 
4.2.1 Study design and population 
The case-control study of acute streptococcal non-necrotizing cellulitis targeted 
individuals presenting with acute cellulitis and erysipelas infections during April 
2004-March 2005. Patients ≥18 years of age hospitalised for acute cellulitis or 
erysipelas infections were recruited into the study from two infectious diseases 
wards in two hospitals in the City of Tampere (catchment population 500,000). 
Patients potentially meeting the case definition were assessed and the diagnosis 
confirmed within 4 days of admission to the hospital by an infectious diseases 
specialist. For each patient, one control subject matched for age, sex, and residence 
was recruited by randomly sampling candidates from the Population Register 
Centre. Where possible, family members sharing the same household as the patients 
were also recruited. 
 
4.2.2 Case definition and exclusion criteria 
Acute, bacterial non-necrotizing cellulitis was defined as either of the following: (1) 
a sudden onset of fever or chills and a localised, more-or-less well-demarcated 
erythema of the skin in the leg or arm or, (2) a typical appearance of well-
demarcated skin eruption on the face, either with or without fever or chills. Thus, 
bacterial cellulitis and erysipelas (as the superficial form of cellulitis) were included 
in the case definition. Patients who had cutaneous abscesses, NF, septic arthritis or 
osteomyelitis were excluded from the study.   
 
4.2.3 Collection of samples  
Samples were collected from the recruited patients using sterile culture and 
transportation tubes (Technical Service Consultants). Skin swab samples were taken 
from any existing wound or blister within the infection focus or if the skin area was 
intact, elsewhere from any abrasion or fissured toe web. A throat swab sample was 
taken from all patients and control subjects and where available from household 
members. Blood samples were drawn from all patients for determination of 
bacteraemia. 
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4.2.4 Culturing and identification of samples 
All skin and throat swabs were sent to THL. The swab was first used to inoculate a 
sheep blood agar plate and then placed in a tube of sterile water in order to obtain a 
bacterial suspension. The suspension was serially diluted and an aliquot of the 
dilutions were plated on sheep blood agar. All plates were incubated in 5% CO2 at 
35°C, and bacterial growth was determined at 24 h and 48 h. β-haemolytic bacterial 
growth was visually examined and recorded and the number of colony forming 
units/ml calculated. From each sample, up to 10 suspected β-haemolytic 
streptococcal colonies and one suspected S. aureus colony were picked for further 
culturing and identification.  
 
The processing and identification of blood cultures from patients was performed by  
the clinical laboratory of the respective hospitals using standard culture systems and 
media (Bactec 9240, BD Diagnostic Systems). Any β-haemolytic streptococcal 
isolates were forwarded to THL on blood agar plates.  
 
All suspected β-haemolytic streptococcal isolates were tested for sensitivity to 
bacitracin and the Streptex latex agglutination test (Remel Europe Ltd) applied to 
detect the Lancefield group antigens A, B, C, D, F, and G. The Staph Slidex Plus 
latex agglutination test (bioMérieux) was used for identification of S. aureus. The 
species of group A, B, and G streptococci were determined by API ID 32 Strep test 
(bioMérieux). Isolates positively identified as β-haemolytic streptococci or S. aureus 
were stored at -70°C.  
 
4.3 Characterisation of isolates 
The methods applied to characterise the invasive S. pyogenes isolates and isolates 
from the case-control study of cellulitis in the different publications of this work is 
described in detail in Table 5.  
 
The invasive isolates were analysed according to the typing methods available in the 
reference laboratory at the time the isolate was received. T serotyping was used for 
characterisation of all isolates during 1995-2006. emm typing was started in 2003 
and used as the primary typing method for all iGAS isolates during 2004-2007. 
Susceptibility to erythromycin, clindamycin, and tetracycline was determined for all 
invasive isolates during 2004-2007 and to levofloxacin for isolates during 2005-
2007. In addition to this scheme, other typing methods such as PFGE and 
superantigen profiling were used selectively for determining the clonal relationship 
of isolates. 
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In the case-control study, isolates of group A (S.pyogenes) and group G (S. 
dysgalactiae subsp. equisimilis) streptococci were characterised by T serotyping, 
emm typing, and PFGE. 
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4.3.1 T serotyping 
T serotyping was performed using the available anti-T agglutination sera: five 
polyvalent and 21 monovalent sera (1, 2, 3, 4, 5, 6, 8, 9, 11, 12, 13, 14, 18, 22, 23, 
25, 27, 28, 44, B3264, and Imp19) (Sevac) according to standard procedure [224].  
 
4.3.2 emm typing 
emm typing was performed according to the Centers of Disease Control and 
Prevention guidelines [45]. The emm gene was amplified using either of two sets of 
primers: MF1 and MR1, and primer1 and primer2 (Table 6). Until 2005, the primer 
set used was MF1 and MR1. Primer1 and primer2 were introduced in 2006 to 
improve the method and minimise the amount of non-typable isolates. MF1 and 
MR1 remained as a secondary choice if the emm gene could not be amplified with 
the primer1 and primer2.  
 
With primers MF1 and MR1, the following PCR conditions were used: initial 
denaturation at 95°C for 10 min and 94°C for 3 min, 35 cycles of denaturation at 
93°C for 30 s, annealing at 54°C for 30 s, and extension at 72°C for 2 min, with a 
final extension step at 72°C for 10 min. With primer 1 and primer 2, PCR conditions 
were as follows: initial denaturation at 95°C for 10 min, 30 cycles of denaturation at 
94°C for 1 min, annealing at 46°C for 1 min, and extension at 72°C for 2.5 min; and 
1 final extension cycle at 72°C for 7 min [310]. PCR products were purified with 
QIAquick PCR Purification Kit (Qiagen) as described by the manufacturer. 
Table 6. Primers used for emm typing. 
Primer Sequence 5’ -> 3’ Reference 
MF1 (forward and 
sequencing) 
ATA AGG AGC ATA AAA ATG GCT [153] 
MR1 (reverse) AGC TTA GTT TTC TTC TTT GCG  [153] 
primer 1 (forward) TAT T(C/G)G CTT AGA AAA TTA A [17, 47] 
primer 2 (reverse) GCA AGT TCT TCA GCT TGT TT [17, 47] 
emmseq2 (sequencing) TAT TCG CTT AGA AAA TTA AAA ACA GG [47] 
 
The emm sequencing reaction was performed with primer MF1 or emmseq2 with 
use of BigDye chemistry (Applied Biosystems), with cycling times of 30 cycles of 
denaturation at 96°C for 20 s, annealing at 55°C for 20 s, and extension at 60°C for 
4 min. Sequence data were analysed using ABI Prism 310 Genetic Analyzer 
(Applied Biosystems) and the sequences obtained compared against the CDC 
Streptococcus pyogenes emm sequence database to assign emm types [45]. 
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4.3.3 Pulsed field gel electrophoresis (PFGE) analysis 
PFGE was performed for selected isolates in studies II and IV using standard 
methods [290]. Bacterial cells were lysed with lysostafin, DNA was digested with 
SmaI (Roche), and restriction fragments were separated with CHEF-DR II (Bio-
Rad) for 23 h, with pulse times of 10-35 s. Bionumerics software (Applied Maths) 
was used for analysing restriction profiles, which were interpreted along general 
guidelines [313]. Strains with ≥90% similarity were considered as the same PFGE 
type; strains with ≥80% similarity were considered as related types. Types were 
designated by uppercase letters (for GAS) or Roman numerals (for GGS). Individual 
strains were termed “unique”.    
 
4.3.4 Superantigen profiling 
Superantigen profiling was performed for selected isolates in study II. Two 
multiplex PCR reactions were performed for detection of pyrogenic exotoxin genes 
speA, speB, speC, speF, speG, speH, and speJ, and the streptococcal superantigen 
ssa gene. A single PCR was used to detect streptococcal mitogenic exotoxin smeZ 
gene [72, 268]. 
 
4.3.5 Antimicrobial susceptibility testing  
Susceptibility to erythromycin, clindamycin, tetracycline, and levofloxacin was 
determined for invasive strains in studies II and III by agar dilution. Susceptibility 
was assigned as the minimum inhibitory concentration (MIC) of a given 
antimicrobial according to interpretative criteria for Streptococcus spp. (other than S. 
pneumoniae) as recommended by the Clinical and Laboratory Standards Institute 
(CLSI) [54]. The MIC was assigned as the lowest antimicrobial concentration 
completely inhibiting bacterial growth. The breakpoints used for the susceptible (S), 
intermediate (I), and resistant (R) categories for these antimicrobials were as 
follows: erythromycin: S ≤ 0.25 mg/l, I = 0.5 mg/l, R ≥ 1 mg/l; clindamycin: S ≤ 
0.25 mg/l, I = 0.5 mg/l, R ≥ 1 mg/l; tetracycline: S ≤ 1 mg/l, I = 2 mg/l, R ≥ 4 mg/l; 
and levofloxacin: S ≤ 1 mg/l, I = 2 mg/l, R ≥ 4 mg/l. 
 
4.4 Data analysis and statistics 
Data on the cases of invasive GAS infection, their outcome, and isolate 
characterisation data (where available) were linked using the national identity code 
of the patient and the date of specimen. Where the national identity code was not 
available (prior to 2004), other available information was used for linkage, such as 
the date of specimen, date of birth of patient and place of treatment. Population data 
were obtained from Statistics Finland. Average annual incidence rates were 
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calculated for 1998-2007 using the population census at the end of the previous year 
as the denominator. Age- and sex-specific incidence rates and male-to-female ratios 
with 95% confidence intervals (CI) were calculated. Case fatality rates (CFR) were 
calculated for 2004-2007 as the number of fatal cases compared to the total number 
of cases for each year. Case fatality by emm type was calculated in a similar manner 
by dividing the number of fatal cases per type with the total number of isolates for 
each emm type separately. For the cellulitis study, only one episode per patient was 
considered when calculating percentages, unless otherwise specified. In clinical 
samples (skin, blood), a patient was considered culture positive for a given bacterial 
group if the culture sample was positive for that bacterial group at any time during 
the study.  
 
Incidence rates and CIs according to the Poisson distribution were calculated using 
R statistical software version 2.9.0 (R Development Core Team). Data were 
analysed using Intercooled Stata™ 9.1 software for Windows (StataCorp) and 
GraphPad software [120]. Fisher’s exact, χ2, and Kruskal-Wallis tests were applied 
where appropriate to test for statistical significance between subgroups and 
distributions. McNemar’s test was used in the case-control study for the comparison 
of differences between pharyngeal bacterial findings of patients and control subjects. 
Differences were considered significant when P<0.05.  
 
4.5 Ethical considerations 
Finnish clinical laboratories mandatorily notify S. pyogenes isolations from blood or 
CSF to the NIDR. THL conducts infectious disease surveillance and research by 
legislation and has the rights to use data from the NIDR and the outcome data from 
the Population Information System for that purpose. The previously unpublished 
incidence data presented in this book were retrieved from the public user interface of 
NIDR [316]. 
 
The patients recruited for the acute cellulitis study signed a declaration confirming 
their informed consent. The acute cellulitis study was approved by the Ethical 
Review Board of Pirkanmaa District, Tampere University Hospital, Finland. 
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5  RESULTS 
5.1 The epidemiology of invasive GAS disease in Finland (I, II, 
III) 
The epidemiology of invasive GAS disease in Finland was studied in detail in the 
publication III, which covered the years 1998-2007. Average annual incidence rates 
from 1995-2004 and 2005-2007 were also presented in publications I and II, 
respectively. An overview of the received notifications and isolates is presented in 
Table 7. 
Table 7. An overview of the number of notifications and isolates included in the 
published works. Data for 2008 retrieved from NIDR [316]. 
Year No. of 
notifications 
received 
No. of 
isolates 
received 
Publication 
1995 58 43 I 
1996 60 58 I 
1997 80 79 I 
1998 105 110 I, III 
1999 116 113 I, III 
2000 116 103 I, III 
2001 100 93 I, III 
2002 153 138 I, III 
2003 119 118 I, III 
2004 130 128 I, III 
2005 110 110 II, III 
2006 162 161 II, III 
2007 207 203 II, III 
2008 221 NAa NA 
Total 1737 1457 NA 
a NA, not applicable. 
  
5.1.1 Annual incidence (I, II, III) 
During 1995-2007, the annual incidence rate fluctuated in the range of 1.1-3.9 cases 
per 100,000 population. Despite fluctuation, an increasing trend was evident, as 
shown in Figure 2. Peaks occurred in 2002 (2.9 cases per 100,000) and in 2006-2007 
(3.1-3.9). The year with the lowest incidence was 1995 (1.1) and troughs also 
occurred in 2001 (1.9) and 2005 (2.1). The incidence continued to increase in 2008 
(4.2 cases per 100,000) [316]. 
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Figure 2. Annual incidence rate of iGAS in Finland, 1995-2008. Data for 2008 
retrieved from NIDR [316]. 
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5.1.2 Incidence by district (III) 
The incidence varied considerably between the 20 healthcare districts, and from 
year-to-year within the districts, owing to the small number of cases observed. Rates 
were therefore examined at the level of tertiary care districts, which include 2-5 
healthcare districts within each of the five tertiary districts. Between these tertiary 
care districts, the average annual incidence rate varied from 1.8-3.1 cases per 
100,000 population during 1998-2007. The annual incidence rate increased in all 
districts by more than 1 case per 100,000 and more than doubled in three out of five 
of these districts. Fourty-one per cent of all cases occurred in the tertiary care district 
around the capital city Helsinki (with the largest population), where the annual 
incidence rate varied within the range of 2.2-4.4 cases per 100,000. 
 
5.1.3 Age- and sex-specific incidence (III) 
A total of 1318 cases of iGAS (range by year, 100-207) were identified during 1998-
2007; the median age of case-patients was 52 years (range 0-95 years). Fifty-five 
percent of the case-patients (N= 719) were male. During the study, the average 
annual incidence rate of iGAS was 2.5 cases per 100,000 population. 
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The average incidence rate was higher in males (2.8) than in females (2.2) and it 
increased by age in adult age groups (Table 8). The highest rates were seen in the 
elderly (≥65 years of age), while the lowest rates were seen in the age groups of 1-24 
years. The rate in males was significantly higher than females especially among 
patients aged 45-64 years. In contrast, females had a significantly higher incidence 
than males among patients aged 25-34 years.  
Table 8. Incidence of invasive group A streptococcal disease by age and sex, 
Finland, 1998-2007.  
 Ratea of invasive disease   
Age group 
(years) 
Male 
(N=719) 
Female 
(N=599) 
Total 
(N=1318) 
Incidence 
rate ratio 
(RR)b 
95% CIc of 
RR 
<1 2.7 2.2 2.5 1.3 0.4-3.9 
1-14 1.2 0.9 1.0 1.3 0.8-2.0 
15-24 0.8 1.2 1.0 0.6 0.4-1.0 
25-34 1.2 2.7 1.9 0.4   0.3-0.6* 
35-44 3.0 2.7 2.8 1.1 0.9-1.5 
45-54 4.2 1.8 3.0 2.4   1.8-3.2* 
55-64 4.8 2.4 3.6 2.0  1.5-2.6* 
≥65 5.1 3.8 4.3 1.4  1.1-1.7* 
All 2.8 2.2 2.5 1.3  1.1-1.4* 
a Average incidence (cases per 100,000 population) 
b male-to-female ratio 
c CI, confidence interval. Statistical significance (P<0.05) is indicated with an asterisk (*). 
 
Males had a higher incidence than females in all study years except 2003, when the 
rates were equal (Table 9). The incidence rate ratio (male-to-female) showed a 
statistically significant difference in 1999 (RR, 1.7) and bordered on significant in 
2004 (1.4) and 2006 (1.4). 
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Table 9. Annual incidence of invasive group A streptococcal disease, Finland, 1998-
2007.  
 Ratea of invasive disease (no. of cases)   
Year Male Female Total Incidence 
rate ratio 
(RR)b 
95% CIc 
of RR 
1998 2.3 (57) 1.8 (48) 2.1 (105) 1.2 0.9-1.8 
1999 2.8 (71) 1.7 (45) 2.2 (116) 1.7  1.1-2.4* 
2000 2.6 (66) 1.9 (50) 2.2 (116) 1.4 1.0-2.0 
2001 2.1 (54) 1.7 (46) 1.9 (100) 1.2 0.8-1.8 
2002 3.0 (77) 2.9 (76) 2.9 (153) 1.1 0.8-1.5 
2003 2.3 (58) 2.3 (61) 2.3 (119) 1.0 0.7-1.4 
2004 2.9 (75) 2.1 (55) 2.5 (130) 1.4 1.0-2.0 
2005 2.3 (58) 1.9 (52) 2.1 (110) 1.2 0.8-1.7 
2006 3.6 (93) 2.6 (69) 3.1 (162) 1.4 1.0-1.9 
2007 4.2 (110) 3.6 (97) 3.9 (207) 1.2 0.9-1.6 
All 2.8 (719) 2.2 (599) 2.5 (1318) 1.3  1.1-1.4* 
a Average annual incidence (cases per 100,000 population) 
b male-to-female ratio 
c CI, confidence interval. Statistical significance (P<0.05) is indicated with an asterisk (*). 
 
5.2 Seasonal patterns of infection (III) 
Seasonal patterns of iGAS infection were examined during 1998-2007. The monthly 
number of cases varied in the range of 3-23, depending on the overall incidence. In 
general, the months with most cases were January, July and December, whereas the 
months with the least cases were September, October and November. Figure 3 
shows the number of iGAS cases over time. A twelve-week moving average was 
used to smooth variation by chance due to relatively small number of cases per 
month and in order to obtain a clearer trendline.  
 
Two peak seasons of iGAS disease could be identified, during the midsummer 
(June-August) and the midwinter (December to February). The peaks during the 
summer were more evident than those during the winter. Both males and females 
had peaks of cases during the winter, whereas the summer peak occurred 
predominantly for males. The overall trend for both sexes was that the least amount 
of iGAS cases occurred during the autumn months (September-November).  
 
 
5  Results 
THL – Research 23/2009 60 
 
Molecular and epidemiological aspects of 
Streptococcus pyogenes disease in Finland: Severe 
infections and bacterial, non-necrotizing cellulitis 
 
 
Figure 3. The monthly number of cases of invasive group A streptococcal disease in 
Finland during 1998-2007.Red line, number of cases; black line, number of cases 
(12-week moving average).  
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5.3 T- and emm type prevalence (I, II, III) 
The typing data from 1995-2003 presented in this book and in publication I is based 
on referred isolates. This number differs slightly from the amount of notifications 
for the same time period. For a small proportion of notifications a matching isolate 
was missing; also, for some referred isolates a matching notification did not exist. 
For the data during 2004-2007, and for publications II and III, only isolates that 
were matched to notifications were included in the analyses. Therefore, the number 
of isolates in 2004 presented in this book differs slightly to the number presented for 
2004 in publication I, which was based on non-matched data.  
 
During 1995-2003, 855 isolates and during 2004-2007, 602 isolates were received 
for characterisation, amounting to 1457 iGAS isolates in total. T typing results of 
1995-2004 were published in the original publication I; results from 2005-2006 are 
previously unpublished. The most common T serotypes encountered in Finland 
during 1995-2006 in order of prevalence were T28 (29%), T1 (13%), TB3264 
(12%), T12 (7%), T8 (6%), T11 (4%), and T3/B6326 (3%) (Figure 4). Depending on 
the year, the seven most common types accounted for 55-87% of the isolates. The 
annual proportion of nontypable (NT) isolates varied within a range of 2-21%.  
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During the study period, the prevalence of common T types was constantly 
changing. First the T1 strains peaked in 1997-1998, after that the prevalence of 
TB3264 strains was the highest in 1999, and the T28 strains had a peak later in 
2003, this type comprising almost half of the iGAS isolates at that time. The 
prevalence of other types seemed to go through less dramatic changes. It is also 
noteworthy that the proportion of nontypable strains increased to over 20% by 2006. 
Figure 4. The proportions of most common T serotypes of Finnish iGAS isolates 
during 1995-2006. The number of isolates received and typed each year is indicated 
with numbers above the bars. The numbers in the bars represent the number of 
isolates for each serotype (indicated for the most common types). Years 1995-2003, 
referred isolates; 2004-2006 referred isolates matching to notifications. Data from 
2005-2006 are previously unpublished.  
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Serotype T28 strains, being the most common type overall during this study period, 
were studied in more detail in publication I. The emm typing results of all isolates of 
serotype T28 during 1995-2006 showed that among isolates that reacted with T28 
antiserum alone or with T28 in combination with other T typing sera (N=391), six 
different emm types were found: emm28 (71.5% of all T28), emm77 (15.5%), 
emm53 (9.5%), emm2 (2%), emm87 (1%), and emm4 (0.5%). Figure 5 illustrates 
how the amount of these emm types among T28 strains fluctuated over time. The 
isolates reacting with T28 antiserum were more heterogeneous during 1997-2000, 
and less heterogeneous in all other years when the isolates were mostly of genotype 
emm28.  
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Figure 5. The emm types of serotype T28 isolates during 1995-2006 in Finland. 
Isolates include strains reacting with T28 antiserum alone (N=358) and T28 in 
combination with any other T typing sera (N=33). Other types include emm2, 
emm87 and emm4. Data from 2005-2006 are previously unpublished. 
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Prior to 2004, the iGAS isolates were selectively characterised by emm typing, but 
comprehensive emm typing data for all isolates exists for 2004-2007. A total of 46 
emm types among 602 isolates were encountered during this time. The proportion of 
nontypable isolates varied annually from 1-5%. The most common emm types 
during 2004-2007 in the order of prevalence were 28 (21%), 1 (16%), 84 (10%), 75 
(7%), and 89 (6%), which together accounted for 48-65% of the isolates depending 
on the year (Figure 6). In 2004, type emm28 was the most predominant type, and its 
proportion gradually declined each year while that of emm1 increased, and by 2007 
emm1 had become the most common type. In 2005, an uncommon type, emm84, 
emerged in Finland and became increasingly prevalent, ranking as the second most 
common type by 2007. Again, similarly to T serotypes, the less common emm types 
showed less fluctuation than the most common types.   
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Figure 6. Ten most common emm types of Finnish iGAS isolates during 2004-2007. 
The number of isolates received and typed each year is indicated with numbers 
above the bars. The numbers in the bars represent the number of isolates for each 
emm type (indicated for the most common types).    
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A comparison of the emm and T typing patterns could be undertaken during the 
period 2004-2006, when these methods were used in unison. Table 10 contains all 
emm and T type combinations encountered in Finland during these three years, and 
shows relationships between emm and T types as well as differences in Finnish type 
combinations in comparison to those obtained by others [159, 200]. 
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Table 10. The emm and T types of invasive GAS isolates collected in Finland during 
2004-2006. T patterns that have been commonly observed by others [159, 200] are 
indicated by bold, underlined font; patterns closely related to these commonly found 
T patterns are indicated by underlined font. Closely related T patterns are separated 
by commas, distinctly different T patterns are separated by semicolons. Table design 
adapted from [159]. 
emm type No. of 
isolates 
No. of T/emm 
combinations 
T type (no. of isolates)a 
1 41 1 1 (41) 
3 1 1 3 
4 8 2 4 (5); NTb (3) 
11 2 2 11 (1), 8/11 (1) 
12 14 1 12 (14) 
22 3 2 12 (1); NT (2) 
25 1 1 1 
27G 8 2 5/27 (6); NT (2) 
28 100 2 28 (97); NT (3) 
44/61 1 1 8/11 
53 2 2 3/B3264 (1); 28 (1) 
59 1 1 NT 
60 2 1 4 (2) 
66 3 2 12 (2), 3/12 (1) 
67 1 1 3 
68 1 1 3/B3264 
69 1 1 3 
73 12 6 3/13 (4), 13 (3), 13/B3264 (1), 3/13/B3264 (1), B3264 
(1); NT (2) 
75 39 4 8/25 (19), 25 (17), 8/25/Imp19 (2), 25/Imp19 (1) 
76 1 1 12 
77 9 6 13/28 (3); Imp19 (2), 8/Imp19 (1), 25/Imp19 (1); 13 (1); 
NT (1) 
78 3 3 11 (1); 3/B3264 (1); NT (1) 
79 26 5 11 (11); 8 (5); 12 (1); B3264 (1); NT (8) 
81 15 4 8 (4); B3264 (3), 3/B3264 (2); NT (6) 
82 1 1 5/27 
83 1 1 8 
84 25 4 11 (9); 3 (2), 3/B3264 (1); NT (13) 
85 9 5 3 (4), 9/3 (2), 3/13 (1), 9/3/13 (1); NT (1) 
87 1 1 28 
89 25 4 3/B3264 (14), B3264 (6); 8 (1); NT (4) 
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102 1 1 3 
104 1 1 8/11 
108 1 1 NT 
110 13 5 11 (5), 5/11 (1); 8 (1); B3264 (1); NT (5) 
112 5 3 8 (1); 11 (3); NT (1) 
118 1 1 13 
122 1 1 NT 
124 2 1 NT 
st75 2 1 25 
st369 1 1 14 
st1389 1 1 NT 
st3850 1 1 NT 
st554 1 1 NT 
stM3 1 1 3 
NAc 10 6 B3264 (3), 3 (2), 3/13 (1), 3/B3264 (1), 3/13/B3264 (1); 
NT (2) 
Total 399 95 - 
a The number of isolates of each specific T/emm-type combination is described within brackets. 
b NT, nontypable. 
c NA, emm type not available (nontypable). 
 
Because of the relatively small numbers of cases, analyses of associations of specific 
emm types and age or sex of the patient were limited to the most common emm 
types. Type emm28 infections were significantly overrepresented in females 
compared to males (55% vs. 45%, respectively; P<0.01). The same was true for type 
emm4 (73% vs. 27%, respectively, P<0.05). More specifically, a significantly larger 
proportion of infections by emm28 were concentrated in females of child-bearing 
age (15-44 years) than males of the same age (48% vs. 21% of emm28 infections, 
respectively; P<0.01).  
 
5.4 Outcome of invasive infections (II, III) 
During 2004-2007, 48 of a total of 609 case-patients died within 7 days of positive 
blood or CSF culture, corresponding to an overall case fatality of 8%. There was no 
significant difference in the case fatality rate in males and females (9% vs. 6%, 
P=0.172). The highest case fatality rate occurred in 2005 (12%), followed by 2006 
(10%), while the year with the lowest rate was 2004 (3%). Case-patients with a fatal 
outcome were older than those who survived the infection (median age, 60 vs. 54 
years; P<0.01). There were no fatalities in the age groups of <1 year and 15-24 
years.   
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The outcome by emm type is presented in Figure 7. Infections by type emm1 were 
significantly associated with a high case fatality rate (14% vs. 8% in all other types; 
P<0.02). Infections caused by emm75 and 79 were also associated with a higher than 
average case fatality (14% for both types). In contrast, the case fatality associated 
with type emm28 infections was low (2% vs. all other types, P<0.01), also true for 
type 81 (0%, respectively). The emm types that contributed most to the case fatality 
were emm1 (29% of all fatal cases; range by year 15-47%), followed by emm75 
(13%, range 0-25%), emm79 (8%, range 6-25%), and emm84 (8%; range 0-20%). 
Case fatality in emm84 infections did not significantly differ to that of all other types 
(7% vs. 8%, respectively).  
 
Figure 7. Distribution of emm types causing iGAS infections according to 7-day 
case fatality, 2004-2007, Finland. Thirteen most common emm types regardless of 
outcome, and all rarer types(N=6) causing at least one fatal case are included. The 
percentages indicate case fatality by emm type (shown for types causing two or 
more infections).  
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5.5 Superantigen profiles in relation to PFGE strain types (II) 
In order to obtain more information about the clonality and virulence factors of 
emm84 isolates, their PFGE and superantigen profiles were studied. PFGE profiling 
was performed for all emm84 isolates during 2005-2007 (N=57). These isolates fell 
into six PFGE strain types, A1 (52 isolates) and A2, B1, B2, C, and D (1 isolate 
each), with related strain types of A1 and A2, and B1 and B2, respectively. The 
strain type A1 predominated until 2007, when sporadic cases with other strain types 
emerged among the emm84 strains. Ten emm84 isolates representing different PFGE 
strain types were selected for superantigen profiling (Table 11). Variability in the T 
types and SAg gene content existed between emm84 isolates of different PFGE 
strain types, but the results of these methods were mainly in concordance, as related 
strain types harboured a similar set of SAg genes.  
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5.6 Antimicrobial susceptibility (II, III) 
All iGAS isolates during 2004-2007 (N=602) were tested for antimicrobial 
resistance to erythromycin, clindamycin, and tetracycline; isolates of 2005-2007 
were also tested for levofloxacin. Overall, 1.5% of the isolates were resistant to 
erythromycin, 0.5% to clindamycin, and 16% to tetracycline; tetracycline resistance 
varied depending on the year (Table 12). The tetracycline resistant strains were 
mainly emm types 81 (20 resistant isolates in total; 87% of this type resistant to 
tetracycline), 27G (19; 100%), 77 (12; 100%), and 85 (9; 100%). In contrast, 
resistance to tetracycline was not common among the most prevalent emm types, 
such as 28 (4% of isolates of this type resistant to tetracycline), 1 (0%), 84 (2%), 75 
(2%), 89 (0%), 79 (0%), and 12 (0%).  
Table 12. Resistance of iGAS isolates to antimicrobials, 2004-2007. 
Resistance (%) Antimicrobial agent  
2004 
N=128 
2005 
N=110 
2006 
N=161 
2007 
N=203 
Erythromycin 1.6 1.8 0.6 2.0 
Clindamycin 0.8 0.0 1.2 0.0 
Tetracycline 22.7 15.5 12.4 15.3 
Levofloxacin NDa 0.0 0.0 0.0 
a ND, not determined. 
 
5.7 Investigation of a cluster of infections (II) 
Infections of type emm84 were primarily located in the largest healthcare district of 
the Helsinki metropolitan area, where type emm84 was the most common type in 
2006 and 2007. In 2006, these infections were treated in several hospitals, one of 
which had a cluster of cases occurring during April-October involving seven 
patients. The isolates were of the major PFGE strain type A1 (Table 11).  
 
Investigation of medical records of these patients revealed that they had no common 
exposure or contacts. All patients had one or more predisposing factor for invasive 
infection, such as traumatic wound, diabetes, intravenous drug use, alcoholism, 
immunodeficiency, and malignancy. None of these infections had fatal outcome. 
 
5.8 Acute bacterial, nonnecrotizing cellulitis in Finland (IV) 
A total of 90 patients presenting with 98 episodes of acute bacterial cellulitis were 
included in the study during April 2004-March 2005. Males dominated among the 
patients (58 men vs. 32 women); the median age of the patients was 58 years (range, 
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21-90 years). Correspondingly to the patients, 90 control subjects and 38 family 
members were recruited in the study.  
 
More cellulitis episodes occurred during the months of July-September than during 
any other three-month period (P<0.05). Sixteen of the 98 episodes could be 
classified as classic erysipelas, the form of cellulitis presenting with a clearly 
demarcated area of inflammation (Figure 8). 
 
Figure 8. A classic erysipelas infection in the leg with a clearly defined area of 
inflammation. The photograph was kindly provided by a participant in the cellulitis 
study.  
 
 
 
Antimicrobial treatment had been initiated in 28% of disease episodes prior to 
sampling. A skin swab sample was taken from 66 patients presenting with a total of 
73 disease episodes. No skin swab was taken from the rest of the patients (N=24), as 
the skin in the infection focus was intact and no other abrasion or wound could be 
found. Excluding recurrent episodes, a total of 24 patients harboured β-haemolytic 
streptococci: GGS (17 patients), GAS (5), GGS+GAS (1), and GBS (1). 
Additionally, two patients (2%) were blood culture positive for GGS. S. aureus was 
isolated from 27 patients, either alone (N=10) or concomitantly with β-haemolytic 
streptococci (N=17). All of the GGS were of the species S. dysgalactiae subsp. 
equisimilis.  
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Of the 24 culture positive samples for β-haemolytic streptococci, 9 were isolated 
from the infection focus and 15 from the suspected site of entry (wound, intertrigo 
etc.). Among the skin swab and blood culture samples, eleven emm types among 20 
GGS isolates and four emm types among six GAS isolates were found (Table 13). 
PFGE analysis of the isolates revealed that none of the strains isolated from different 
patients were identical, with the exception of the emm81 isolates, which were part of 
a cluster of cases in a nursing home. Thus, no clear predominance of a specific emm 
type was seen. 
Table 13. emm types of group G and A streptococci isolated from acute bacterial 
cellulitis. Excluding recurrences; only one isolate of a streptococcal group per 
patient is included. 
Group 
antigen 
emm type No. of 
isolates 
Sample site 
G stC74A 1 skin 
G stC6979 2 skin; blood 
G stG6.0 2 skin 
G stG6.1 2 skin 
G stG11 1 skin 
G stG166b 2 skin 
G stG245 2 skin 
G stG480 2 skin 
G stG485 2 skin; blood 
G stG643 3 skin 
G stG5420 1 skin 
A emm28 1 skin 
A emm73 1 skin 
A emm81 3 skin 
A emm85 1 skin 
 
5.7.1 Recurrent infections (IV) 
Six patients (five males, one female) had recurrent episodes during the study; four 
patients had two episodes and two patients had three episodes. The median age of 
these patients was 48 years. The time between recurrences varied between 46 and 
156 days (median 81 days). All of these patients had a history of at least one 
previous cellulitis infection. GGS was isolated from three of these patients, 
concomitantly with S. aureus. In two patients, the same strain of GGS (emm types 
stG6.0 and stG11) with identical PFGE profile was isolated from two consecutive 
episodes.  
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5.7.2 Pharyngeal carriage (IV) 
Pharyngeal carriage of β-haemolytic streptococci was studied from the patients, their 
household members and control subjects. Throat swabs were obtained from all but 
one patient (N=89) and from all other study subjects (90 control subjects, 38 
household members). β-haemolytic streptococci were present in the pharynx of 13% 
of patients, 21% of household members, and 10% of control subjects (Figure 9). 
Among these isolates, GGS was significantly more commonly found from patients 
than control subjects (7% vs. 0%, respectively; P<0.04). Thirteen percent of 
household members of the patients also harboured GGS. S. aureus was present in 
≤10% of the samples of these groups. 
 
One patient carried the same GGS strain of emm type stG245 with identical PFGE 
type III in the pharynx and affected skin. On two occasions, the same strain was 
shared within a household. Those were the following: one patient and a household 
member harboured identical clones of GGS type stG480 with PFGE type II in their 
pharynx, and two members of the same household shared the same clone of GGS 
stG6.1. 
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6  DISCUSSION 
This study describes the epidemiology of invasive S. pyogenes infections in Finland 
over more than a decade-long period of nationwide population-based surveillance. 
Overall, annual and age- and sex-specific incidence rates were calculated. Seasonal 
patterns and outcome due to these infections were studied. The study size of over 
1500 cases of iGAS disease accumulated over the years provided a large enough 
sample for scientific analysis. Bacterial cellulitis infections caused by β-haemolytic 
streptococci were studied in the first population-based clinical study within a 
defined region in Finland. The S. pyogenes isolates causing invasive disease and 
cellulitis were characterised with both conventional and molecular typing methods. 
More detailed analyses were undertaken on isolates representing the most common 
type (T28) and one emerging type (emm84). The main findings and limitations of 
this study are discussed below.  
 
6.1 The epidemiology of invasive S. pyogenes disease in 
Finland  
This study has shown that the incidence of iGAS disease in Finland fluctuated since 
the 1990s but had an increasing trend. The increase was especially steep during the 
later years, from 2006 onwards. The incidence rate of 3.9 cases per 100,000 
population observed in 2007 was the highest since 1995, with further increases 
noted beyond this study in 2008, reaching 4.2/100,000 [316]. During 2003-2004, the 
UK, Sweden, Denmark, and Finland had the highest rates of infection (range 2.5-3.3 
per 100,000) in Europe [185]. Indications of a very recent increase in incidence can 
be seen in the UK and Sweden, whereas the rate has remained relatively stable in the 
USA during this decade [46, 183, 244, 287]. It remains to be seen if the present 
influx will be a temporary phenomenon or if the number of these infections will 
continue to increase in Finland. Although invasive S. pyogenes infections are still 
quite rare, the trend is worrying, especially as means of preventing these infections 
are limited.  
 
Comparisons of incidence rates are complicated by differences in case definitions 
between countries. The surveillance scheme of invasive GAS disease in Finland 
includes, according to the case definition, only cases with a blood or CSF isolate. 
Non-bacteraemic cases with other sterile site isolations, including those who 
develop life-threatening complications such as STSS are excluded. This may partly 
explain the lower incidence rate observed in Finland, as in many other countries a 
broader definition of iGAS disease is used. Furthermore, differences between the 
healthcare districts in terms of blood culture sampling practices, diagnostic 
6  Discussion 
THL – Research 23/2009 75 
 
Molecular and epidemiological aspects of 
Streptococcus pyogenes disease in Finland: Severe 
infections and bacterial, non-necrotizing cellulitis 
 
 
procedures, and use of automated blood culture instruments may also have had an 
effect on the incidence rate over time [176, 284]. 
 
Although it is known that individuals of all ages are affected by iGAS disease, the 
elderly and small children generally have the highest incidence. Also in Finland, the 
incidence generally increased with age, but the rate in the elderly patients (65 years 
of age) remained at a lower level than has been reported in Sweden, Denmark, the 
UK, and the USA [72, 184, 198, 244]. Similarly, the incidence in infants (<1 years) 
was similar to other Nordic countries and lower than in the UK, the USA, Canada, 
and Australia [72, 184, 198, 243, 244, 322].  
 
Males had a higher incidence than females during this study. A slight male 
dominance in iGAS infections has also been noted by others [185, 188, 243, 244]. 
Differences in the age- and sex-specific rates could also be identified, with male 
patients being overrepresented among the patients aged 45-64 years. In contrast, 
more infections occurred in females than males aged 25-34 years. Earlier studies 
from Denmark and the UK noticed a similar peak in the incidence in females around 
the same age [184, 198]. Presumably there are many different factors contributing to 
these distinctions, such as sex-specific differences in risk factors, notably pregnancy, 
social behaviour (including the use of alcohol and drugs), occupation, and the 
threshold of seeking medical care in case of trauma.  
 
Spatial and temporal variations in incidence, interspersed with occasional peaks, are 
known to characterise this disease and were also observed in this study [185, 244]. 
The incidence in the 20 healthcare districts varied considerably over time and in 
comparison to each other, partly due to the small population of some of these 
districts. The fluctuation in incidence is thought to be a reflection of dynamic 
changes in the emm type distribution, but also of population susceptibility to 
particular strains [72, 168, 242, 244]. The emergence of new types not previously 
encountered by a population may have a profound influence on the incidence.  
 
The good coverage and efficient functioning of the national mandatory infectious 
disease notification system of Finland is a strength of this study. A corresponding 
isolate was received for approximately 94% of the notifications during 1995-2003 
and for 99% of the notifications during 2004-2007. However, there are also some 
limitations to these findings. Firstly, the lower level of incidence during the first 
three study years (1995-1997) may be an artefact due to the transition into a new 
notification system in 1995, with notifications being potentially sub-optimal at first, 
affecting the coverage of the data. Thus, the actual incidence during these years may 
have been higher. However, from 1998 the notification procedure seems to have 
become well established and therefore the recent increase in incidence during the 
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2000s appears to be real and not due to improved notification. Secondly, the fact that 
the case-definition includes only bacteraemic cases influences the observed 
incidence, as some invasive infections (some GAS sterile site isolations and STSS) 
would be excluded. Finally, the surveillance system does not include collection of 
clinical data on disease manifestations, possible risk factors and underlying 
conditions. These data would be needed to address reasons behind the observed 
differences in the age- and sex-specific incidence. Recently, such a study has been 
undertaken within a defined area of one healthcare district in Finland, and earlier in 
1995 through enhanced surveillance (unpublished) [256].  
 
6.2 Molecular characteristics of invasive S. pyogenes strains 
During this study, shifts in the type distribution of iGAS in Finland were seen; first 
with changes in T type and later emm type prevalence. Comparisons of results of T 
and emm typing were limited to the years 2004-2006 during which period both 
methods were used. Based on these results and observations by others, the T and 
emm typing results correlate especially well with type 1 (e.g. T1 strains are mostly 
M/emm1) and reasonably well with type 28 [99, 159]. In contrast, the isolates of 
types TB3264, T8, and T12 most likely represent a large pool of different emm 
types, similarly as the emm types 84, 75, and 89 are likely to represent several 
different T types. For this reason, and for ease of comparison to other countries, it 
was more rational to concentrate more on the recent emm typing instead of the T 
typing results.    
 
Major changes occurred in the emm type distribution of iGAS in Finland during 
2004-2007 when the most dominant type, emm28, was replaced by emm1. An 
overall increase in incidence of iGAS disease occurred in parallel to type emm1 
increasing in prevalence, also observed in other studies [73, 96, 300, 305, 334]. 
However, changes in the prevalence of other emm types, such as the emergence of 
type emm84, may have also contributed to the increase in incidence.  
 
The emm type distribution of iGAS isolates in Finland shares common features with 
that of other countries but also has unique characteristics. emm types 1, 28, and 89 
are common globally but 75 and 84 are rarer and have not been mentioned among 
the five most common types elsewhere [72, 90, 150, 198, 243, 244, 322, 333]. 
Another interesting characteristic in the molecular epidemiology of Finnish GAS 
disease is low prevalence of infections by emm3, a common type in many other 
countries including Scandinavia, and often associated with high case fatality [150, 
198, 219, 226, 242-244, 322, 333]. The reason for the near absence of emm3 is 
unclear, particularly as there has been some exposure to this type in Finland, judging 
by the small number of sporadic infections seen. The emm types that are included in 
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the putative 26-valent recombinant vaccine would have covered approximately 60% 
of the Finnish isolates in 2004, but slightly less than half of the isolates during the 
last two study years; this being a smaller coverage than has been estimated for the 
USA and Japan [150, 216, 244]. 
 
During the last two decades in Finland, a periodic fluctuation of some of the 
common types has occurred. Peaks in numbers of T/M/emm1 cases were observed in 
1988-1990, 1997-1998, and 2006-2007 [139, 228]. In contrast, T/M/emm28 peaked 
in 1993-1995 and 2002-2004 [228]. The alternating prevalence of these two major 
types, with epidemics of each type with an interval of approximately 8-10 years, 
may be a reflection of strain competition. A similar if not as clear a pattern of 
fluctuation of these types has occured also in other Nordic countries. Epidemics by 
M/emm1 were observed in 1988 in Sweden and Norway (synchronously with 
Finland), during 1999-2002 in Denmark and during 1994-1995 again in Sweden [89, 
96, 219, 300, 305]. Similarly, M/emm28 was dominant during 1996-1997 in Sweden 
and during 2003-2004 in both Sweden and Denmark (synchronously with Finland) 
[98, 200]. However, some caution should be used in comparing these findings given 
the different typing methods employed. As said before, even though with types 1 
and 28, the T, M and emm typing results correlate reasonably well, some variation in 
the strains is evident and uncommon type combinations are encountered [159].  
 
The reasons for the seemingly constant flux in the type prevalence are not yet clear. 
One suggested explanation is the tendency of a population to develop immunity after 
a certain time towards a prevalent type, causing the type to decrease in prevalence, 
creating a niche for other types. In a similar fashion, the emm types of pharyngeal 
paediatric isolates seem to have age-associated differences, which may be a 
reflection of an aquired immunity towards more common types as a consequence of 
exposure in early life [151].  
 
Type emm28 and more rarely also emm4 have been shown to be associated with 
postpartum infections and puerperal sepsis [51, 59, 323, 322, 333]. Similarly, in this 
study, emm28 infections were concentrated in females of child-bearing age. 
However, estimations of how many of these infections may have been pregnancy-
related were beyond the scope of this study. No particular emm types were found to 
be concentrated specifically in males.  
 
The rapid emergence of an uncommon type, emm84, in 2006-2007 was of specific 
interest because of the low prevalence of this type in other countries. These isolates 
were found to be mostly of clonal origin. The analysis of medical records of a 
cluster of emm84 cases could not identify a common exposure or contacts between 
the patients. Instead, it became evident that all patients had one or more 
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predisposing factors for infection, emphasizing the role of these factors in invasive 
disease.  
 
During the 1990s, type emm84 was found to predominate among erythromycin-
resistant strains causing noninvasive infections in children in Greece, and has also 
been a common type in the UK [88, 336]. Apart from these findings, only sporadic 
infections by emm84 have been reported [181, 201, 260, 307, 314]. However, even 
though it appears that emm84 emerged as a new type in Finland, one cannot be 
certain that this type has not been present before, as extensive data on emm typing 
exists only from 2004 onwards. Type emm84 would not have been detected with T 
typing, the primary typing method until 2003, as it is nonspecific for this emm type. 
emm84 is not included in the putative 26-valent vaccine currently under clinical 
trial. The vaccine types may need re-evaluation in the future in order to adapt to 
changes in emm type prevalence to ensure the vaccine’s coverage [56, 179, 216, 
242]. 
 
A high proportion of Finnish iGAS isolates were susceptible to the antimicrobial 
agents tested. The overall erythromycin resistance during 2004-2007 was low, 
having been in decline during this decade in both blood and pharyngeal isolates  
[108]. This is regarded to be a consequence of nationwide restrictions on the use of 
antimicrobials. Finnish S. pyogenes strains remain susceptible to clindamycin. 
Denmark and the USA have reported similar low resistance rates [198, 260]. 
Tetracycline resistance in Finnish iGAS isolates were found to be associated with 
certain clones, as has also been found previously, with the resistant strains being 
mainly uncommon emm types [172].  
 
This study also addressed the usability of different typing methods for the purpose 
of epidemiological surveillance. T serotyping alone was found to be an insufficient 
method for determining clonality in the Finnish material, with several genotypes 
existing among the serotype T28 isolates (publication I). Generally, emm typing is 
the method of choice for characterisation of GAS isolates in many countries, 
including Finland. However, when the Finnish emm84 isolates were further 
characterised with PFGE and SAg profiling, they were found not to be of clonal 
origin (publication II). For some emm types, such as emm1, two or more circulating 
subtypes can be found at the same time and they can be considered 
epidemiologically as distinct types, but with further characterisation, isolates of a 
specific subtype may also prove to be nonclonal. Therefore, for the purpose of 
general epidemiological surveillance, emm typing alone is a sufficient and cost-
effective method, but for cluster or outbreak investigations, it should be 
complimented with PFGE typing, and if applicable, with other methods such as SAg 
profiling or antimicrobial susceptibility testing. When both emm and PFGE typing 
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are performed together, they provide the sufficient discriminatory power needed for 
clonality analyses. However, the use of PFGE for typing of all isolates is not feasible 
as it is very time-consuming, the same being true for MLST. The implementation of 
MLST, instead of PFGE, into the typing scheme to supplement the emm typing 
results would offer some advantages for clonality analyses, but compared to PFGE, 
MLST lacks discriminatory power.  
 
6.3 Streptococcal non-necrotizing cellulitis 
In the case-control study of acute bacterial non-necrotizing cellulitis, strikingly, the 
most common bacterial finding was of group G streptococcus (S. dysgalactiae 
subsp. equisimilis) instead of GAS. Some of the case-patients and their household 
members also carried GGS as part of their pharyngeal flora, whereas it was not 
found in control subjects. GGS was isolated either from the skin or blood in 22% of 
patients, while GAS was isolated only from 7% of patients. This finding was in 
contrast to earlier knowledge of cellulitis which regarded the group A streptococcus 
(S. pyogenes) as the main causative agent [48, 94, 304]. However, some other 
studies have noticed a stronger role of GGS in acute cellulitis than expected [94, 
148], and a recent case-control study in Iceland found these bacteria in similar 
proportions as in our study [35]. In our study, the proportion of patients with a 
positive blood culture result (2%) was in the expected range for this disease [31, 37, 
94, 161]. This study found a slight but non-significant male predominance among 
patients presenting with acute cellulitis, also been found by others [35, 94, 191, 
223]. Presumably the sex-specific differences in risk factors play an equally 
important role in cellulitis as in invasive infections.   
 
Group G streptococci (S. dysgalactiae subsp. equisimilis) are known to be closely 
similar to GAS in their genetic and molecular properties, as well as in the clinical 
spectrum of infections, and similar predisposing factors have been identified for 
infections by both organisms [134, 160, 163]. Research strongly supports that 
horizontal transfer of virulence genes occurs between GAS and GGS strains [74, 75, 
165]. GGS strains have been increasingly recognised as a cause of pharyngitis, skin 
and soft tissue infections, bacteraemia and toxic shock [209, 332]. Similarly, studies 
from Denmark and Israel have noticed an increase in the frequency of GGS 
bacteraemias during the 1990s, with a probable source of skin or soft tissue infection 
identified in the majority of cases [134, 306]. Our knowledge of the prevalence of 
GGS bacteraemia in Finland is limited, since it is not among the notifiable diseases. 
A population-based study undertaken in one healthcare district in Finland found that 
the incidence of GGS bacteraemia was higher than GAS bacteraemia and had a 
similarly increasing trend [256]. Seventy percent of the bacteraemic GGS infections 
(equally many as with GAS bacteraemias) presented with a skin or soft tissue 
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infection. A change in the epidemiology of β-haemolytic bacteraemia may be 
occurring, and possibly also with cellulitis towards an increasing aetiological role of 
GGS over GAS [306].  
 
The finding that only 13% of the cellulitis patients were carrying β-haemolytic 
streptococci in their throat is concordant with other studies [94]. GGS was more 
commonly recovered from the throat than GAS, similar to an Australian study on the 
epidemiology of GGS [209]. It has been assumed that throat carriage of GAS and 
group C or G streptococci may be independent of each other and almost mutually 
exclusive [209]. This study was in line with this hypothesis. One of the patients in 
this study harboured the same GGS strain in both the pharynx and affected skin. In 
this case, it is impossible to say if the respiratory tract is the reservoir for the 
pathogen. However, colonisation of skin prior to infection has been reported and it is 
a far more likely origin to the infection [161].  
 
In this study, there was no predominance of a specific emm type of GGS or GAS 
associated with the disease. The knowledge of emm types of GGS and GAS causing 
cellulitis infections is very limited. In an earlier study in Sweden, serotypes T1 and 
T8 dominated in GAS isolates from cellulitis patients [240]. Many of the GGS emm 
types found in this study have been mentioned in relation to invasive disease [57, 
127, 165, 196]. Similarly, the emm types of GAS found in cases of cellulitis 
(including emm28) were also encountered among the invasive isolates of this study. 
The small number of GAS isolates found in cellulitis infections did not allow for 
detailed comparisons of the emm types with the invasive isolates.  
 
A limitation to this study is that the case patient population consisted of hospitalised 
patients with cellulitis infections of intermediate severity. The proportion of patients 
treated on an outpatient basis is not known. The Finnish treatment recommendation 
is that febrile patients with cellulitis should be hospitalised for initial parenteral 
antimicrobial treatment. The most severe cases of cellulitis, e.g. patients requiring 
intensive care treatment or surgery, were not eligible for inclusion in this study as 
they were treated in other wards. This fact may have lowered the observed rate of 
bacteraemia and the rate of recurrence, which may be further underestimated by the 
short study period and lack of follow-up [62]. As such, the true incidence of these 
infections in Finland cannot be estimated based on this study. Comparisons between 
countries are also complicated by the broad spectrum of severity of these diseases 
and differences in treatment practices. A study from the Netherlands stated that only 
7% of all patients presenting with cellulitis of the leg were hospitalised, and another 
study from the USA estimated that 5.7% of cellulitis patients were treated in in-
patient hospital settings (such as our study) and 20.5% in acute care settings and 
outpatient hospitals [91, 116]. In another approximation from the UK, of those with 
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three or more episodes of cellulitis, half of recurrences led to hospital admission 
[62].  
 
As a further limitation to this study, the possibility cannot be excluded that the 
choice of sampling method and, for some cases, antimicrobial treatment prior to 
sampling (in 28% of episodes) may have affected the bacterial findings. By using a 
non-invasive sampling method, β-haemolytic streptococci could be isolated from 
one-third of the samples taken. However, when the infection site was intact, the 
sample was taken from the suspected site of entry, such as any abrasion or fissured 
toe-web, if such a site was detected. The findings differed by sampling site, and 
more than half of the isolates (and more specifically, GGS) were obtained from the 
suspected site of entry, which may or may not have been the actual site of entry of 
the pathogen. Nevertheless, recent findings support the role of toe webs as a 
potential site of entry, with colonisation of toe webs by pathogens having been 
identified as a risk factor for lower-limb cellulitis [35, 133].   
 
One further limitation concerns the size and duration of the case-control study. Even 
though a study including almost a hundred case patients and control subjects within 
a one-year period was considered to be large enough to enable conclusions with 
sufficient statistical power, a study with longer duration and a follow-up period 
would have been of benefit to obtain more microbiological isolates and considerably 
more information about the recurrences and seasonal trends of infections. Inclusion 
of twice the number of controls per case patient would have helped increase the 
power of the study.   
 
6.4 Recurrent cellulitis 
Within the one year study period, six (7%) of the patients had a recurrence of 
cellulitis, with four patients having two disease episodes and two patients having 
three episodes. According to earlier studies, in 20-30% of patients with bacterial 
cellulitis the infection recurs within a three-year follow-up period [94, 162]. GGS 
could be isolated in three patients and GBS in one patient of the six patients with 
recurrences. For two of these patients, the consecutive disease episodes could be 
confirmed as being caused by an identical clone of GGS, strongly supporting the 
concept of a relapse. Whether recurrences of cellulitis are specifically associated 
with a streptococcal species (namely, S. dysgalactiae subsp. equisimilis), or even a 
specific streptococcal strain, is yet undefined. GGS has been known to cause 
recurrent bacteraemia [57]. The notion of the same streptococcal strain causing a 
relapse raises the question of how the pathogen evades the antimicrobial treatment. 
Intracellular persistence during acute soft tissue infections may be a mechanism of 
GAS for avoiding eradication by the antimicrobial [317]. The recurrences may also 
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be associated with individual variation in immunological response, with some 
patients more susceptible to the infection and unable to clear the bacteria from the 
infection site.  
 
As many as 50% of the case-patients in this study reported having suffered previous 
episodes of cellulitis prior to this study. In addition to various general and local risk 
factors for infection, such as oedema, disruption of the cutaneous barrier, and being 
overweight, a previous cellulitis infection in itself seems to predispose to future 
episodes by causing scarring and damage to tissue and lymphatic circulation [9, 35, 
62, 94, 191, 223, 265]. The median age of the case-patients with recurrences was 48 
years; 10 years less than that of other case-patients. All case-patients were also 
studied for risk factors for infection (outside the scope of this PhD thesis), and 
although the study was underpowered to identify risk factors specifically for 
recurrences, oedema, broken skin, and being overweight were identified as risk 
factors for an acute cellulitis infection [169]. In one retrospective study from France, 
age (and to a lesser extent, sex) was identified as a relevant factor for recurrent 
infections, with younger patients having a higher risk for recurrences [191]. 
 
Streptococcal cellulitis remains a disease of high morbidity [92]. Recurrences 
represent a major problem affecting patient’s quality of life and incurring 
considerable costs in the form of hospitalisation, sick leave, and disability. It has 
been estimated that a large proportion of these infections could be preventable by 
increased awareness and management of toe-web intertrigo and by adequate 
treatment of dermatomycosis (fungal infection), a key risk factor for infection [35, 
265].  
 
6.5 Seasonality of S. pyogenes infections 
Seasonal variation in iGAS disease incidence in Finland was observed, with 
occasional peaks of cases occurring during midwinter and midsummer. In Europe, 
the USA, and Canada, peaks are generally observed during the first months of the 
year (winter and spring) [72, 185, 244, 322, 334]. The unusual pattern and 
irregularity of the seasonality observed in Finland may be partly due to natural 
variation given the reasonably small study size. Several factors may be associated 
with seasonality, including environmental changes (temperature, humidity, annual 
light/dark cycle) or host-behavioural patterns (differences in outdoor activities, 
depending on sex and academic season) [82]. Viral respiratory infections may 
predispose to bacterial infections, as has been shown to occur with pneumococcal 
infections [175, 308]. Presumably there are different predisposing factors and 
underlying conditions associated with the two distinct peaks. In a study within one 
healthcare district in Finland, the predisposing factor in over half of GAS 
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bacteraemias was disruption of the cutaneous barrier, which may occur 
predominantly in the summer season [256].  
 
In the case-control study, more episodes of acute cellulitis occurred during the 
summer (July-September) than in other study periods. A study from the USA also 
concluded that cellulitis was most common during the summer and least common 
during the winter [91]. A hospital in the UK reported seeing a marked seasonal 
variation in cellulitis with a peak of cases in May [129]. A case-control study 
reported more cases of cellulitis during the summer in Tunis [223], where the 
climatic conditions during the hot season nonetheless differ considerably from those 
of Finland. In contrast, some studies have observed more cellulitis cases in the 
winter or no seasonal variation at all [48, 94, 148, 161]. Nevertheless, skin infections 
in general may be more common during the summer, due to increased outdoor 
activities, swimming, and increased exposure of the skin to insect bites and minor 
trauma, for example during gardening work [129, 264]. Furthermore, the higher 
temperature and humidity in the summer may delay the healing of wounds and 
increase predisposition to toe-web intertrigo, providing a portal of entry for the 
pathogen and increasing the risk of cellulitis.   
 
6.6 Outcome of S. pyogenes infections 
The overall case fatality of invasive GAS infections in Finland was 8% during 2004-
2007, which is low compared to rates encountered in some European countries and 
the USA [72, 90, 184, 244]. A sudden peak in the case fatality (12%) occurred in 
2005, partly explained by the changing emm type distribution. The proportion of 
infections by types associated with a higher than average case fatality, namely, 
emm1 and emm75, increased. In parallel, the proportion of emm28 decreased, this 
type being associated with a lower than average case fatality. The case fatality of 
infections by emm84 was of specific interest because of its rareness and rapid 
emergence in Finland. The overall CFR associated with emm84 infection was 7%, 
not differing significantly from the average case fatality. Sixty per cent of the fatal 
cases were associated with the five most common emm types, thus, the case fatality 
was affected mostly by changes in their prevalence.  
 
Although infections by specific emm types were associated with different rates of 
case fatality, the virulence of a given strain is not solely due to the properties of the 
M protein, but rather a combination of the strain’s various virulence factors. Even 
though certain SAg profiles have been found to be more frequent among invasive 
isolates, the association between pathogenic potential and the presence of single 
SAg genes is not completely clear [49, 72]. Furthermore, properties of the host, such 
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as age, underlying diseases, and the function of the immune system are vital in 
determining the course and outcome of infection [15, 292].  
 
Comparisons of case fatality rates between different studies are complicated by 
differences in case definitions, such as the inclusion or exclusion of nonbacteraemic 
cases with other sterile site isolations and/or STSS, the timing of death (7-day, 30-
day or in-hospital mortality), and sources of outcome information (e.g. population 
registry vs. hospital records). In this study, 7-day mortality information was obtained 
from the Population Information System instead of hospital records. A strength of 
the outcome analyses is the completeness and coverage of the registry-based 
information. However, the same limitation of the case definition affects the case 
fatality rates. The exclusion of non-bacteraemic cases with other sterile site 
isolations such as joint aspirates, or cases of STSS without bacteraemia, may have 
an increasing or decreasing impact on the observed case fatality rate.  
 
Although cellulitis may be fatal, usually these cases are associated with low 
mortality. The severity of illness has been shown to increase with age but also with 
the presence of comorbidities such as diabetes [116]. Patients who produce higher 
levels of cytokines in response to streptococcal SAgs have been shown to develop 
more severe systemic manifestations [236]. The intracellular presence of the 
pathogen, which has been shown to occur with acute soft tissue infections, may lead 
to attenuated immune response, characterised by the lower level of inflammation 
[317]. Thus, the reason for low mortality due to cellulitis may be more related to the 
properties of the human immune response than of the pathogen. Patients with 
cellulitis may also produce higher levels of toxin-neutralizing antibodies than 
patients with sepsis [240]. 
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7  CONCLUSIONS AND FUTURE CONSIDERATIONS 
The incidence of invasive group A streptococcal (S. pyogenes) disease has had an 
increasing trend during the last ten years in Finland, following a general European 
pattern and remaining at a relatively high level. In general, small children and the 
elderly had the highest incidence, although the rates in these age groups in Finland 
have remained at a similar or lower level than in other Nordic countries. Presumably 
differences in the predisposing factors and underlying conditions contribute to the 
observed age- and sex-specific differences in the incidence rate. Collection of 
clinical data is needed in order to fully understand the influence of these factors and 
to try and prevent infections in specific risk groups. Setting-up a nationwide 
collection of clinical data would demand considerable personnel resources in the 
healthcare districts, and for this reason such a study has recently been performed 
only within a defined area of Pirkanmaa district. Future studies could be targeted at 
the largest healthcare district, the Helsinki metropolitan area, in order to ensure that 
the study has enough power to detect possible associations, for example between 
disease manifestations and certain emm types.  
 
The incidence of iGAS disease in Finland is influenced by dynamic and rapid 
changes occurring in the strain type distribution due to inter-strain competition. Two 
strain types, T/emm1 and T/emm28, were common throughout the study period and 
their prevalence fluctuated in turn with each other. The prevalence of infections by 
type emm1 had the highest impact on incidence, but the sudden emergence of 
emm84 and other less common types also contributed to the increase. The emm types 
of the putative recombinant M-protein based vaccine would have covered only half 
of the isolates during recent years due to unique features in the Finnish type 
distribution as compared to that in other developed countries.  
 
A new and unexpected finding of this study was that instead of group A 
streptococcus, group G streptococcus (S. dysgalactiae subsp. equisimilis) 
predominated in acute cellulitis infections in Finland. A predominance of GGS was 
also seen in the pharynx of case-patients and their family members, whereas the 
control subjects did not harbour GGS. No specific emm type of GGS or GAS 
associated with the disease. The recurrent nature of cellulitis became evident during 
the study and in two recurrences, the consecutive disease episodes were caused by 
an identical clone of GGS.  
 
The molecular epidemiology of group G streptococcus, being genetically close to 
GAS and causing clinically similar infections, would be worthy of further research. 
Sequencing of the streptococcal genomes of other species than S. pyogenes would 
bring more perspective to the research of streptococcal diseases [142]. Also, further 
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studies of the inflammatory responses during a cellulitis infection would shed more 
light on why these infections tend to persist, and possibly provide a means to 
prevent recurrences, decreasing the suffering of patients and hospitalisation costs. 
The GGS strains found in this study could be further characterised to examine their 
virulence properties, for example with SAg profiling.  
 
A seasonal pattern with occasional peaks of cases during the midwinter and 
midsummer was observed in invasive infections, differing from the general seasonal 
trend of a peak in the winter or spring. Presumably these peak seasons are associated 
with different predisposing factors and underlying conditions. Comparisons of 
seasonal patterns between neighbouring countries and on different hemispheres 
could yield more information on the undoubtedly multiple factors associated with 
seasonality. More cellulitis infections were also found to occur during the summer, 
which may be associated with predisposition to toe-web intertrigo due to higher 
temperature and humidity during the summer.   
 
The case fatality of S. pyogenes infections was found to be at a reasonably low level 
in Finland compared to other countries, despite a temporary peak in the case fatality 
during the latest study years. Cases with type emm1 were associated with higher 
than average case fatality, whereas emm28 infections were associated with lower 
than average case fatality. Dynamic changes in the strain type prevalence had an 
influence on the incidence and case fatality, with changes in the prevalence of the 
most common types such as emm1, emm28 and emm84 having the highest impact. 
These strains could be further characterised for their SAg profiles and other 
virulence factors in relation to outcome.  
 
The emm typing method was found to be sufficient for the purpose of general 
epidemiological surveillance; higher discriminatory power could be achieved when 
complementing it with PFGE. Research into the molecular epidemiology of 
streptococci would benefit from development and implementation of novel 
molecular methods for typing and characterisation. Ideally, a typing method would 
provide a “fingerprint” of selected characteristics of the strain (e.g. virulence, 
genetic origin, antimicrobial resistance), have good discriminatory power for 
detecting clonality, and be quick and easy to perform. The oligonucleotide 
microarray technology could offer a versatile solution for the characterisation of 
GAS.   
 
This study adds to our understanding of the molecular epidemiology of S. pyogenes 
infections in Finland and provides a basis for comparison to other countries and 
future trends. Global emm type surveillance and outcome analyses remain important 
in order to rapidly detect changes in the type distribution that might lead to increase 
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in the incidence and mortality. Early identification of iGAS infections is of 
importance in the initiation of prompt treatment to improve patient outcome. 
Monitoring of antimicrobial resistance is needed in order to react to a possible 
resistance problem in a timely manner with appropriate national guidance on choice 
of antimicrobials. Identification of strain types serves as basis for studies of disease 
pathogenesis and vaccine development. 
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